

18103047D

SENATE BILL NO. 505

Offered January 10, 2018

Prefiled January 9, 2018

A *BILL to amend and reenact §§ 54.1-2400.01:1, 54.1-2400.9, 54.1-2900, 54.1-2901, 54.1-3300, 54.1-3300.1, 54.1-3301, 54.1-3303, 54.1-3401, as it is currently effective and as it shall become effective, 54.1-3408, 54.1-3482.1, and 54.1-3812 of the Code of Virginia and to amend the Code of Virginia by adding sections numbered 54.1-2953.1 through 54.1-2953.4, relating to a doctorate of medical science; licensure and practice.*

Patron—Carrico (By Request)

Referred to Committee on Education and Health

Be it enacted by the General Assembly of Virginia:

1. That §§ 54.1-2400.01:1, 54.1-2400.9, 54.1-2900, 54.1-2901, 54.1-3300, 54.1-3300.1, 54.1-3301, 54.1-3303, 54.1-3401, as it is currently effective and as it shall become effective, 54.1-3408, 54.1-3482.1, and 54.1-3812 of the Code of Virginia are amended and reenacted and that the Code of Virginia is amended by adding sections numbered 54.1-2953.1 through 54.1-2953.4 as follows:

§ 54.1-2400.01:1. Surgery defined; who may perform surgery.

A. For the purposes of this subtitle, except as used in Chapter 38 (§ 54.1-3800 et seq.) related to veterinary medicine, "surgery" means the structural alteration of the human body by the incision or cutting into of tissue for the purpose of diagnostic or therapeutic treatment of conditions or disease processes by any instrument causing localized alteration or transposition of live human tissue, but does not include the following: procedures for the removal of superficial foreign bodies from the human body, punctures, injections, dry needling, acupuncture, or removal of dead tissue. For the purposes of this section, incision shall not mean the scraping or brushing of live tissue.

B. No person shall perform surgery unless he is (i) licensed by the Board of Medicine as a doctor of medicine, osteopathy, or podiatry; (ii) licensed by the Board of Dentistry as a doctor of dentistry; (iii) jointly licensed by the Boards of Medicine and Nursing as a nurse practitioner; (iv) *a doctorate of medical science acting in accordance with his practice agreement*; (v) a physician assistant acting under the supervision of a doctor of medicine, osteopathy, or podiatry; ~~(vi)~~ (vi) a licensed midwife in the performance of episiotomies during childbirth; or ~~(vii)~~ (vii) acting pursuant to the orders and under the appropriate supervision of a licensed doctor of medicine, osteopathy, podiatry, or dentistry.

C. Nothing in this section shall be construed to restrict, limit, change, or expand the scope of practice in effect on January 1, 2012, of any profession licensed by any of the health regulatory boards within the Department of Health Professions.

§ 54.1-2400.9. Reporting disabilities of drivers.

Any (i) doctor of medicine, osteopathy, chiropractic, or podiatry; (ii) nurse practitioner; (iii) *doctorate of medical science*; (iv) physician assistant; ~~(iv)~~ (v) optometrist; ~~(v)~~ (vi) physical therapist; or ~~(vi)~~ (vii) clinical psychologist who reports to the Department of Motor Vehicles the existence, or probable existence, of a mental or physical disability or infirmity of any person licensed to operate a motor vehicle which the reporting practitioner believes affects such person's ability to operate a motor vehicle safely shall not be subject to civil liability under § 32.1-127.1:03 resulting from such report or deemed to have violated the practitioner-patient privilege unless he has acted in bad faith or with malicious intent.

§ 54.1-2900. Definitions.

As used in this chapter, unless the context requires a different meaning:

"Acupuncturist" means an individual approved by the Board to practice acupuncture. This is limited to "licensed acupuncturist" which means an individual other than a doctor of medicine, osteopathy, chiropractic or podiatry who has successfully completed the requirements for licensure established by the Board (approved titles are limited to: Licensed Acupuncturist, Lic.Ac., and L.Ac.).

"Auricular acupuncture" means the subcutaneous insertion of sterile, disposable acupuncture needles in predetermined, bilateral locations in the outer ear when used exclusively and specifically in the context of a chemical dependency treatment program.

"Board" means the Board of Medicine.

"Certified nurse midwife" means an advanced practice registered nurse who is certified in the specialty of nurse midwifery and who is jointly licensed by the Boards of Medicine and Nursing as a nurse practitioner pursuant to § 54.1-2957.

"Certified registered nurse anesthetist" means an advanced practice registered nurse who is certified

INTRODUCED

SB505

59 in the specialty of nurse anesthesia, who is jointly licensed by the Boards of Medicine and Nursing as a
60 nurse practitioner pursuant to § 54.1-2957, and who practices under the supervision of a doctor of
61 medicine, osteopathy, podiatry, or dentistry but is not subject to the practice agreement requirement
62 described in § 54.1-2957.

63 *"Doctorate of medical science" means an individual who has met the requirements of the Board for*
64 *licensure.*

65 "Genetic counselor" means a person licensed by the Board to engage in the practice of genetic
66 counseling.

67 "Healing arts" means the arts and sciences dealing with the prevention, diagnosis, treatment and cure
68 or alleviation of human physical or mental ailments, conditions, diseases, pain or infirmities.

69 "Medical malpractice judgment" means any final order of any court entering judgment against a
70 licensee of the Board that arises out of any tort action or breach of contract action for personal injuries
71 or wrongful death, based on health care or professional services rendered, or that should have been
72 rendered, by a health care provider, to a patient.

73 "Medical malpractice settlement" means any written agreement and release entered into by or on
74 behalf of a licensee of the Board in response to a written claim for money damages that arises out of
75 any personal injuries or wrongful death, based on health care or professional services rendered, or that
76 should have been rendered, by a health care provider, to a patient.

77 "Nurse practitioner" means an advanced practice registered nurse who is jointly licensed by the
78 Boards of Medicine and Nursing pursuant to § 54.1-2957.

79 "Occupational therapy assistant" means an individual who has met the requirements of the Board for
80 licensure and who works under the supervision of a licensed occupational therapist to assist in the
81 practice of occupational therapy.

82 "Patient care team" means a multidisciplinary team of health care providers actively functioning as a
83 unit with the management and leadership of one or more patient care team physicians for the purpose of
84 providing and delivering health care to a patient or group of patients.

85 "Patient care team physician" means a physician who is actively licensed to practice medicine in the
86 Commonwealth, who regularly practices medicine in the Commonwealth, and who provides management
87 and leadership in the care of patients as part of a patient care team.

88 "Physician assistant" means an individual who has met the requirements of the Board for licensure
89 and who works under the supervision of a licensed doctor of medicine, osteopathy, or podiatry.

90 "Practice of acupuncture" means the stimulation of certain points on or near the surface of the body
91 by the insertion of needles to prevent or modify the perception of pain or to normalize physiological
92 functions, including pain control, for the treatment of certain ailments or conditions of the body and
93 includes the techniques of electroacupuncture, cupping and moxibustion. The practice of acupuncture
94 does not include the use of physical therapy, chiropractic, or osteopathic manipulative techniques; the
95 use or prescribing of any drugs, medications, serums or vaccines; or the procedure of auricular
96 acupuncture as exempted in § 54.1-2901 when used in the context of a chemical dependency treatment
97 program for patients eligible for federal, state or local public funds by an employee of the program who
98 is trained and approved by the National Acupuncture Detoxification Association or an equivalent
99 certifying body.

100 "Practice of athletic training" means the prevention, recognition, evaluation, and treatment of injuries
101 or conditions related to athletic or recreational activity that requires physical skill and utilizes strength,
102 power, endurance, speed, flexibility, range of motion or agility or a substantially similar injury or
103 condition resulting from occupational activity immediately upon the onset of such injury or condition;
104 and subsequent treatment and rehabilitation of such injuries or conditions under the direction of the
105 patient's physician or under the direction of any doctor of medicine, osteopathy, chiropractic, podiatry, or
106 dentistry, while using heat, light, sound, cold, electricity, exercise or mechanical or other devices.

107 "Practice of behavior analysis" means the design, implementation, and evaluation of environmental
108 modifications, using behavioral stimuli and consequences, to produce socially significant improvement in
109 human behavior, including the use of direct observation, measurement, and functional analysis of the
110 relationship between environment and behavior.

111 "Practice of chiropractic" means the adjustment of the 24 movable vertebrae of the spinal column,
112 and assisting nature for the purpose of normalizing the transmission of nerve energy, but does not
113 include the use of surgery, obstetrics, osteopathy or the administration or prescribing of any drugs,
114 medicines, serums or vaccines. "Practice of chiropractic" shall include performing the physical
115 examination of an applicant for a commercial driver's license or commercial learner's permit pursuant to
116 § 46.2-341.12 if the practitioner has (i) applied for and received certification as a medical examiner
117 pursuant to 49 C.F.R. Part 390, Subpart D and (ii) registered with the National Registry of Certified
118 Medical Examiners.

119 "Practice of genetic counseling" means (i) obtaining and evaluating individual and family medical
120 histories to assess the risk of genetic medical conditions and diseases in a patient, his offspring, and

other family members; (ii) discussing the features, history, diagnosis, environmental factors, and risk management of genetic medical conditions and diseases; (iii) ordering genetic laboratory tests and other diagnostic studies necessary for genetic assessment; (iv) integrating the results with personal and family medical history to assess and communicate risk factors for genetic medical conditions and diseases; (v) evaluating the patient's and family's responses to the medical condition or risk of recurrence and providing client-centered counseling and anticipatory guidance; (vi) identifying and utilizing community resources that provide medical, educational, financial, and psychosocial support and advocacy; and (vii) providing written documentation of medical, genetic, and counseling information for families and health care professionals.

"Practice of medicine or osteopathic medicine" means the prevention, diagnosis and treatment of human physical or mental ailments, conditions, diseases, pain or infirmities by any means or method.

"Practice of occupational therapy" means the therapeutic use of occupations for habilitation and rehabilitation to enhance physical health, mental health, and cognitive functioning and includes the evaluation, analysis, assessment, and delivery of education and training in basic and instrumental activities of daily living; the design, fabrication, and application of orthoses (splints); the design, selection, and use of adaptive equipment and assistive technologies; therapeutic activities to enhance functional performance; vocational evaluation and training; and consultation concerning the adaptation of physical, sensory, and social environments.

"Practice of podiatry" means the prevention, diagnosis, treatment, and cure or alleviation of physical conditions, diseases, pain, or infirmities of the human foot and ankle, including the medical, mechanical and surgical treatment of the ailments of the human foot and ankle, but does not include amputation of the foot proximal to the transmetatarsal level through the metatarsal shafts. Amputations proximal to the metatarsal-phalangeal joints may only be performed in a hospital or ambulatory surgery facility accredited by an organization listed in § 54.1-2939. The practice includes the diagnosis and treatment of lower extremity ulcers; however, the treatment of severe lower extremity ulcers proximal to the foot and ankle may only be performed by appropriately trained, credentialed podiatrists in an approved hospital or ambulatory surgery center at which the podiatrist has privileges, as described in § 54.1-2939. The Board of Medicine shall determine whether a specific type of treatment of the foot and ankle is within the scope of practice of podiatry.

"Practice of radiologic technology" means the application of ionizing radiation to human beings for diagnostic or therapeutic purposes.

"Practice of respiratory care" means the (i) administration of pharmacological, diagnostic, and therapeutic agents related to respiratory care procedures necessary to implement a treatment, disease prevention, pulmonary rehabilitative, or diagnostic regimen prescribed by a practitioner of medicine or osteopathic medicine; (ii) transcription and implementation of the written or verbal orders of a practitioner of medicine or osteopathic medicine pertaining to the practice of respiratory care; (iii) observation and monitoring of signs and symptoms, general behavior, general physical response to respiratory care treatment and diagnostic testing, including determination of whether such signs, symptoms, reactions, behavior or general physical response exhibit abnormal characteristics; and (iv) implementation of respiratory care procedures, based on observed abnormalities, or appropriate reporting, referral, respiratory care protocols or changes in treatment pursuant to the written or verbal orders by a licensed practitioner of medicine or osteopathic medicine or the initiation of emergency procedures, pursuant to the Board's regulations or as otherwise authorized by law. The practice of respiratory care may be performed in any clinic, hospital, skilled nursing facility, private dwelling or other place deemed appropriate by the Board in accordance with the written or verbal order of a practitioner of medicine or osteopathic medicine, and shall be performed under qualified medical direction.

"Qualified medical direction" means, in the context of the practice of respiratory care, having readily accessible to the respiratory therapist a licensed practitioner of medicine or osteopathic medicine who has specialty training or experience in the management of acute and chronic respiratory disorders and who is responsible for the quality, safety, and appropriateness of the respiratory services provided by the respiratory therapist.

"Radiologic technologist" means an individual, other than a licensed doctor of medicine, osteopathy, podiatry, or chiropractic or a dentist licensed pursuant to Chapter 27 (§ 54.1-2700 et seq.), who (i) performs, may be called upon to perform, or is licensed to perform a comprehensive scope of diagnostic or therapeutic radiologic procedures employing ionizing radiation and (ii) is delegated or exercises responsibility for the operation of radiation-generating equipment, the shielding of patient and staff from unnecessary radiation, the appropriate exposure of radiographs, the administration of radioactive chemical compounds under the direction of an authorized user as specified by regulations of the Department of Health, or other procedures that contribute to any significant extent to the site or dosage of ionizing radiation to which a patient is exposed.

"Radiologic technologist, limited" means an individual, other than a licensed radiologic technologist,

182 dental hygienist, or person who is otherwise authorized by the Board of Dentistry under Chapter 27
183 (§ 54.1-2700 et seq.) and the regulations pursuant thereto, who performs diagnostic radiographic
184 procedures employing equipment that emits ionizing radiation that is limited to specific areas of the
185 human body.

186 "Radiologist assistant" means an individual who has met the requirements of the Board for licensure
187 as an advanced-level radiologic technologist and who, under the direct supervision of a licensed doctor
188 of medicine or osteopathy specializing in the field of radiology, is authorized to (i) assess and evaluate
189 the physiological and psychological responsiveness of patients undergoing radiologic procedures; (ii)
190 evaluate image quality, make initial observations, and communicate observations to the supervising
191 radiologist; (iii) administer contrast media or other medications prescribed by the supervising radiologist;
192 and (iv) perform, or assist the supervising radiologist to perform, any other procedure consistent with the
193 guidelines adopted by the American College of Radiology, the American Society of Radiologic
194 Technologists, and the American Registry of Radiologic Technologists.

195 "Respiratory care" means the practice of the allied health profession responsible for the direct and
196 indirect services, including inhalation therapy and respiratory therapy, in the treatment, management,
197 diagnostic testing, control, and care of patients with deficiencies and abnormalities associated with the
198 cardiopulmonary system under qualified medical direction.

199 **§ 54.1-2901. Exceptions and exemptions generally.**

200 A. The provisions of this chapter shall not prevent or prohibit:

201 1. Any person entitled to practice his profession under any prior law on June 24, 1944, from
202 continuing such practice within the scope of the definition of his particular school of practice;

203 2. Any person licensed to practice naturopathy prior to June 30, 1980, from continuing such practice
204 in accordance with regulations promulgated by the Board;

205 3. Any licensed nurse practitioner from rendering care in collaboration and consultation with a
206 patient care team physician as part of a patient care team pursuant to § 54.1-2957 or any nurse
207 practitioner licensed by the Boards of Nursing and Medicine in the category of certified nurse midwife
208 practicing pursuant to subsection H of § 54.1-2957 when such services are authorized by regulations
209 promulgated jointly by the Board of Medicine and the Board of Nursing;

210 4. Any registered professional nurse, licensed nurse practitioner, graduate laboratory technician or
211 other technical personnel who have been properly trained from rendering care or services within the
212 scope of their usual professional activities which shall include the taking of blood, the giving of
213 intravenous infusions and intravenous injections, and the insertion of tubes when performed under the
214 orders of a person licensed to practice medicine or osteopathy, a nurse practitioner, *a doctor of medical*
215 *science*, or a physician assistant;

216 5. Any dentist, pharmacist or optometrist from rendering care or services within the scope of his
217 usual professional activities;

218 6. Any practitioner licensed or certified by the Board from delegating to personnel supervised by
219 him, such activities or functions as are nondiscretionary and do not require the exercise of professional
220 judgment for their performance and which are usually or customarily delegated to such persons by
221 practitioners of the healing arts, if such activities or functions are authorized by and performed for such
222 practitioners of the healing arts and responsibility for such activities or functions is assumed by such
223 practitioners of the healing arts;

224 7. The rendering of medical advice or information through telecommunications from a physician
225 licensed to practice medicine in Virginia or an adjoining state, or from a licensed nurse practitioner, to
226 emergency medical personnel acting in an emergency situation;

227 8. The domestic administration of family remedies;

228 9. The giving or use of massages, steam baths, dry heat rooms, infrared heat or ultraviolet lamps in
229 public or private health clubs and spas;

230 10. The manufacture or sale of proprietary medicines in this Commonwealth by licensed pharmacists
231 or druggists;

232 11. The advertising or sale of commercial appliances or remedies;

233 12. The fitting by nonitinerant persons or manufacturers of artificial eyes, limbs or other apparatus or
234 appliances or the fitting of plaster cast counterparts of deformed portions of the body by a nonitinerant
235 bracer or prosthetist for the purpose of having a three-dimensional record of the deformity, when
236 such bracer or prosthetist has received a prescription from a licensed physician, licensed nurse
237 practitioner, or licensed physician assistant directing the fitting of such casts and such activities are
238 conducted in conformity with the laws of Virginia;

239 13. Any person from the rendering of first aid or medical assistance in an emergency in the absence
240 of a person licensed to practice medicine or osteopathy under the provisions of this chapter;

241 14. The practice of the religious tenets of any church in the ministration to the sick and suffering by
242 mental or spiritual means without the use of any drug or material remedy, whether gratuitously or for
243 compensation;

15. Any legally qualified out-of-state or foreign practitioner from meeting in consultation with legally licensed practitioners in this Commonwealth;

16. Any practitioner of the healing arts licensed or certified and in good standing with the applicable regulatory agency in another state or Canada when that practitioner of the healing arts is in Virginia temporarily and such practitioner has been issued a temporary authorization by the Board from practicing medicine or the duties of the profession for which he is licensed or certified (i) in a summer camp or in conjunction with patients who are participating in recreational activities, (ii) while participating in continuing educational programs prescribed by the Board, or (iii) by rendering at any site any health care services within the limits of his license, voluntarily and without compensation, to any patient of any clinic which is organized in whole or in part for the delivery of health care services without charge as provided in § 54.1-106;

17. The performance of the duties of any active duty health care provider in active service in the army, navy, coast guard, marine corps, air force, or public health service of the United States at any public or private health care facility while such individual is so commissioned or serving and in accordance with his official military duties;

18. Any masseur, who publicly represents himself as such, from performing services within the scope of his usual professional activities and in conformance with state law;

19. Any person from performing services in the lawful conduct of his particular profession or business under state law;

20. Any person from rendering emergency care pursuant to the provisions of § 8.01-225;

21. Qualified emergency medical services personnel, when acting within the scope of their certification, and licensed health care practitioners, when acting within their scope of practice, from following Durable Do Not Resuscitate Orders issued in accordance with § 54.1-2987.1 and Board of Health regulations, or licensed health care practitioners from following any other written order of a physician not to resuscitate a patient in the event of cardiac or respiratory arrest;

22. Any commissioned or contract medical officer of the army, navy, coast guard or air force rendering services voluntarily and without compensation while deemed to be licensed pursuant to § 54.1-106;

23. Any provider of a chemical dependency treatment program who is certified as an "acupuncture detoxification specialist" by the National Acupuncture Detoxification Association or an equivalent certifying body, from administering auricular acupuncture treatment under the appropriate supervision of a National Acupuncture Detoxification Association certified licensed physician or licensed acupuncturist;

24. Any employee of any assisted living facility who is certified in cardiopulmonary resuscitation (CPR) acting in compliance with the patient's individualized service plan and with the written order of the attending physician not to resuscitate a patient in the event of cardiac or respiratory arrest;

25. Any person working as a health assistant under the direction of a licensed medical or osteopathic doctor within the Department of Corrections, the Department of Juvenile Justice or local correctional facilities;

26. Any employee of a school board, authorized by a prescriber and trained in the administration of insulin and glucagon, when, upon the authorization of a prescriber and the written request of the parents as defined in § 22.1-1, assisting with the administration of insulin or administering glucagon to a student diagnosed as having diabetes and who requires insulin injections during the school day or for whom glucagon has been prescribed for the emergency treatment of hypoglycemia;

27. Any practitioner of the healing arts or other profession regulated by the Board from rendering free health care to an underserved population of Virginia who (i) does not regularly practice his profession in Virginia, (ii) holds a current valid license or certificate to practice his profession in another state, territory, district or possession of the United States, (iii) volunteers to provide free health care to an underserved area of the Commonwealth under the auspices of a publicly supported all volunteer, nonprofit organization that sponsors the provision of health care to populations of underserved people, (iv) files a copy of the license or certification issued in such other jurisdiction with the Board, (v) notifies the Board at least five business days prior to the voluntary provision of services of the dates and location of such service, and (vi) acknowledges, in writing, that such licensure exemption shall only be valid, in compliance with the Board's regulations, during the limited period that such free health care is made available through the volunteer, nonprofit organization on the dates and at the location filed with the Board. The Board may deny the right to practice in Virginia to any practitioner of the healing arts whose license or certificate has been previously suspended or revoked, who has been convicted of a felony or who is otherwise found to be in violation of applicable laws or regulations. However, the Board shall allow a practitioner of the healing arts who meets the above criteria to provide volunteer services without prior notice for a period of up to three days, provided the nonprofit organization verifies that the practitioner has a valid, unrestricted license in another state;

28. Any registered nurse, acting as an agent of the Department of Health, from obtaining specimens

of sputum or other bodily fluid from persons in whom the diagnosis of active tuberculosis disease, as defined in § 32.1-49.1, is suspected and submitting orders for testing of such specimens to the Division of Consolidated Laboratories or other public health laboratories, designated by the State Health Commissioner, for the purpose of determining the presence or absence of tubercle bacilli as defined in § 32.1-49.1;

29. Any physician of medicine or osteopathy or nurse practitioner from delegating to a registered nurse under his supervision the screening and testing of children for elevated blood-lead levels when such testing is conducted (i) in accordance with a written protocol between the physician or nurse practitioner and the registered nurse and (ii) in compliance with the Board of Health's regulations promulgated pursuant to §§ 32.1-46.1 and 32.1-46.2. Any follow-up testing or treatment shall be conducted at the direction of a physician or nurse practitioner;

30. Any practitioner of one of the professions regulated by the Board of Medicine who is in good standing with the applicable regulatory agency in another state or Canada from engaging in the practice of that profession when the practitioner is in Virginia temporarily with an out-of-state athletic team or athlete for the duration of the athletic tournament, game, or event in which the team or athlete is competing;

31. Any person from performing state or federally funded health care tasks directed by the consumer, which are typically self-performed, for an individual who lives in a private residence and who, by reason of disability, is unable to perform such tasks but who is capable of directing the appropriate performance of such tasks; or

32. Any practitioner of one of the professions regulated by the Board of Medicine who is in good standing with the applicable regulatory agency in another state from engaging in the practice of that profession in Virginia with a patient who is being transported to or from a Virginia hospital for care; or

33. Any doctorate of medical science from rendering care in collaboration and consultation with a patient care team physician as part of a patient care team pursuant to § 54.1-2953.2 when such services are authorized by regulations promulgated by the Board.

B. Notwithstanding any provision of law or regulation to the contrary, military medical personnel, as defined in § 2.2-2001.4, while participating in a pilot program established by the Department of Veterans Services pursuant to § 2.2-2001.4, may practice under the supervision of a licensed physician or podiatrist.

§ 54.1-2953.1. Doctorate of medical science; licensure.

A. It shall be unlawful for a person to practice or to hold himself out as practicing as a doctorate of medical science or to use in connection with his name the words or letters "Doctorate of Medical Science" or "D.M.S." unless he holds a license as such issued by the Board.

B. The Board shall promulgate regulations establishing the requirements for licensure as a doctorate of medical science. Such regulations shall include provisions for (i) the application process, (ii) appropriate application and renewal fees, (iii) requirements for licensure renewal and revocation, (iv) continuing education requirements, and (v) any other requirements the Board deems necessary.

C. An applicant for licensure as a doctorate of medical science shall submit evidence satisfactory to the Board that the applicant (i) holds an active unrestricted license to practice as a physician assistant in the Commonwealth or another jurisdiction and can demonstrate engagement in active clinical practice as a physician assistant under physician supervision for at least three years; (ii) is a graduate of a minimum two-year doctorate of medical science program, or an equivalent program that (a) is accredited by a regional body under the U.S. Department of Education and an accrediting body approved by the Board, (b) is taught at an accredited medical or osteopathic school, and (c) trains doctorate of medical science candidates to the same standard of care as the standard of care of a physician; (iii) has successfully completed the Doctor of Medical Science examination determined by the Board; and (iv) is affiliated with a physician who is actively practicing in Commonwealth as a patient care team physician at a hospital or group medical practice engaged in primary care.

§ 54.1-2953.2. Practice of doctorates of medical science; practice agreements.

A. As used in this section:

"Collaboration" means the communication and decision-making process among members of a patient care team related to the treatment and care of a patient and includes (i) communication of data and information about the treatment and care of a patient, including exchange of clinical observations and assessments, and (ii) development of an appropriate plan of care, including decisions regarding the health care provided, accessing and assessment of appropriate additional resources or expertise, and arrangement of appropriate referrals, testing, or studies.

"Consultation" means the communicating of data and information, the exchanging of clinical observations and assessments, the accessing and assessing of additional resources and expertise, problem-solving, and arranging for referrals, testing, or studies.

B. A doctorate of medical science shall practice only as part of a patient care team at a hospital or group medical practice engaged in primary care. Each member of a patient care team shall have

specific responsibilities related to the care of the patient or patients and shall provide health care services within the scope of his usual professional activities. Doctorates of medical science practicing as part of a patient care team shall maintain appropriate collaboration and consultation, as evidenced in a written or electronic practice agreement, with at least one patient care team physician. Collaboration and consultation among doctorates of medical science and patient care team physicians may be provided through telemedicine as described in § 38.2-3418.16. Practice of patient care teams in all settings shall include the periodic review of patient charts or electronic health records and may include visits to the site where health care is delivered in the manner and at the frequency determined by the patient care team.

C. Physicians on patient care teams may require that a doctorate of medical science be covered by a professional liability insurance policy with limits equal to the current limitation on damages set forth in § 8.01-581.15. Service on a patient care team by a patient care team member shall not, by the existence of such service alone, establish or create liability for the actions or inactions of other team members.

D. The Board shall promulgate regulations establishing the scope of practice of a doctorate of medical science and specifying collaboration and consultation among physicians and doctorates of medical science working as part of patient care teams that shall include the development of, and periodic review and revision of, a written or electronic practice agreement; guidelines for availability and ongoing communications that define consultation among the collaborating parties and the patient; and periodic joint evaluation of the services delivered. Practice agreements shall include a provision for appropriate physician input in complex clinical cases and patient emergencies and for referrals. Evidence of a practice agreement shall be maintained by a doctorate of medical science and provided to the Board upon request. For doctorates of medical science providing care to patients within a hospital or health care system, the practice agreement may be included as part of documents delineating the clinical privileges or the electronic or written delineation of duties and responsibilities of the doctorate of medical science in collaboration and consultation with a patient care team physician.

§ 54.1-2953.3. Prescription of certain controlled substances and devices by licensed doctorates of medical science.

A. In accordance with the provisions of this section and pursuant to the requirements of Chapter 33 (§ 54.1-3300 et seq.), a licensed doctorate of medical science shall have the authority to prescribe Schedule II through Schedule VI controlled substances and devices as set forth in Chapter 34 (§ 54.1-3400 et seq.). Doctorates of medical science shall have such prescriptive authority upon the provision to the Board of such evidence as it may require that the doctorate of medical science has entered into and is, at the time of writing a prescription, a party to a written or electronic practice agreement with a patient care team physician that clearly states the prescriptive practices of the doctorate of medical science. Such written or electronic practice agreements shall include the controlled substances the doctorate of medical science is or is not authorized to prescribe and may restrict such prescriptive authority as described in the practice agreement. Evidence of a practice agreement shall be maintained by a doctorate of medical science pursuant to § 54.1-2953.2. Practice agreements authorizing a doctorate of medical science to prescribe controlled substances or devices pursuant to this section shall either be signed by the patient care team physician who is practicing as part of a patient care team with the doctorate of medical science or shall clearly state the name of the patient care team physician who has entered into the practice agreement with the doctorate of medical science.

B. It shall be unlawful for a doctorate of medical science to prescribe controlled substances or devices pursuant to this section unless such prescription is authorized by the written or electronic practice agreement.

C. The Board shall promulgate such regulations governing the prescriptive authority of doctorates of medical science as are deemed reasonable and necessary to ensure an appropriate standard of care for patients.

Regulations promulgated pursuant to this section shall include, at a minimum, such requirements as may be necessary to ensure continued doctorate of medical science competency, which may include continuing education, testing, or any other requirement, and shall address the need to promote ethical practice, an appropriate standard of care, patient safety, the use of new pharmaceuticals, and appropriate communication with patients.

D. The following restrictions shall apply to any doctorate of medical science authorized to prescribe drugs and devices pursuant to this section:

1. The doctorate of medical science shall disclose to the patient at the initial encounter that he is a licensed doctorate of medical science. Any member of a patient care team shall disclose, upon request of a patient or his legal representative, the name of the patient care team physician and information regarding how to contact the patient care team physician.

2. Physicians shall not serve as a patient care team physician on a patient care team at any one time to more than six doctorates of medical science.

428 *E. This section shall not prohibit a licensed doctorate of medical science from administering*
429 *controlled substances in compliance with the definition of "administer" in § 54.1-3401 or from receiving*
430 *and dispensing manufacturers' professional samples of controlled substances in compliance with the*
431 *provisions of this section.*

432 **§ 54.1-2953.4. When doctorate of medical science signature accepted.**

433 *Whenever any law or regulation requires a signature, certification, stamp, verification, affidavit, or*
434 *endorsement by a physician, it shall be deemed to include a signature, certification, stamp, verification,*
435 *affidavit, or endorsement by a doctorate of medical science.*

436 **§ 54.1-3300. Definitions.**

437 *As used in this chapter, unless the context requires a different meaning:*

438 "Board" means the Board of Pharmacy.

439 "Collaborative agreement" means a voluntary, written, or electronic arrangement between one
440 pharmacist and his designated alternate pharmacists involved directly in patient care at a single physical
441 location where patients receive services and (i) any person licensed to practice medicine, osteopathy, or
442 podiatry together with any person licensed, registered, or certified by a health regulatory board of the
443 Department of Health Professions who provides health care services to patients of such person licensed
444 to practice medicine, osteopathy, or podiatry; (ii) a physician's office as defined in § 32.1-276.3,
445 provided *that* such collaborative agreement is signed by each physician participating in the collaborative
446 practice agreement; (iii) any licensed physician assistant working under the supervision of a person
447 licensed to practice medicine, osteopathy, or podiatry; (iv) *any licensed doctorate of medical science*
448 *working as part of a patient care team as defined in § 54.1-2900; or* ~~(iv)~~ (v) any licensed nurse
449 practitioner working as part of a patient care team as defined in § 54.1-2900, involved directly in patient
450 care which authorizes cooperative procedures with respect to patients of such practitioners. Collaborative
451 procedures shall be related to treatment using drug therapy, laboratory tests, or medical devices, under
452 defined conditions or limitations, for the purpose of improving patient outcomes. A collaborative
453 agreement is not required for the management of patients of an inpatient facility.

454 "Dispense" means to deliver a drug to an ultimate user or research subject by or pursuant to the
455 lawful order of a practitioner, including the prescribing and administering, packaging, labeling, or
456 compounding necessary to prepare the substance for delivery.

457 "Pharmacist" means a person holding a license issued by the Board to practice pharmacy.

458 "Pharmacy" means every establishment or institution in which drugs, medicines, or medicinal
459 chemicals are dispensed or offered for sale, or a sign is displayed bearing the word or words
460 "pharmacist," "pharmacy," "apothecary," "drugstore," "druggist," "drugs," "medicine store," "drug
461 sundries," "prescriptions filled," or any similar words intended to indicate that the practice of pharmacy
462 is being conducted.

463 "Pharmacy intern" means a student currently enrolled in or a graduate of an approved school of
464 pharmacy who is registered with the Board for the purpose of gaining the practical experience required
465 to apply for licensure as a pharmacist.

466 "Pharmacy technician" means a person registered with the Board to assist a pharmacist under the
467 pharmacist's supervision.

468 "Practice of pharmacy" means the personal health service that is concerned with the art and science
469 of selecting, procuring, recommending, administering, preparing, compounding, packaging, and
470 dispensing of drugs, medicines, and devices used in the diagnosis, treatment, or prevention of disease,
471 whether compounded or dispensed on a prescription or otherwise legally dispensed or distributed, and
472 shall include the proper and safe storage and distribution of drugs; the maintenance of proper records;
473 the responsibility of providing information concerning drugs and medicines and their therapeutic values
474 and uses in the treatment and prevention of disease; and the management of patient care under the terms
475 of a collaborative agreement as defined in this section.

476 "Supervision" means the direction and control by a pharmacist of the activities of a pharmacy intern
477 or a pharmacy technician whereby the supervising pharmacist is physically present in the pharmacy or in
478 the facility in which the pharmacy is located when the intern or technician is performing duties
479 restricted to a pharmacy intern or technician, respectively, and is available for immediate oral
480 communication.

481 Other terms used in the context of this chapter shall be defined as provided in Chapter 34
482 (§ 54.1-3400 et seq.) unless the context requires a different meaning.

483 **§ 54.1-3300.1. Participation in collaborative agreements; regulations to be promulgated by the**
484 **Boards of Medicine and Pharmacy.**

485 A pharmacist and his designated alternate pharmacists involved directly in patient care may
486 participate with (i) any person licensed to practice medicine, osteopathy, or podiatry together with any
487 person licensed, registered, or certified by a health regulatory board of the Department of Health
488 Professions who provides health care services to patients of such person licensed to practice medicine,
489 osteopathy, or podiatry; (ii) a physician's office as defined in § 32.1-276.3, provided *that* such

collaborative agreement is signed by each physician participating in the collaborative practice agreement; (iii) any licensed physician assistant working under the supervision of a person licensed to practice medicine, osteopathy, or podiatry; *(iv) any licensed doctorate of medical science working as part of a patient care team as defined in § 54.1-2900; or ~~(iv)~~ (v) any licensed nurse practitioner working as part of a patient care team as defined in § 54.1-2900, involved directly in patient care in collaborative agreements which authorize cooperative procedures related to treatment using drug therapy, laboratory tests, or medical devices, under defined conditions or limitations, for the purpose of improving patient outcomes. However, no person licensed to practice medicine, osteopathy, or podiatry shall be required to participate in a collaborative agreement with a pharmacist and his designated alternate pharmacists, regardless of whether a professional business entity on behalf of which the person is authorized to act enters into a collaborative agreement with a pharmacist and his designated alternate pharmacists.*

No patient shall be required to participate in a collaborative procedure without such patient's consent. A patient who chooses to not participate in a collaborative procedure shall notify the prescriber of his refusal to participate in such collaborative procedure. A prescriber may elect to have a patient not participate in a collaborative procedure by contacting the pharmacist or his designated alternative pharmacists or by documenting the same on the patient's prescription.

Collaborative agreements may include the implementation, modification, continuation, or discontinuation of drug therapy pursuant to written or electronic protocols, provided implementation of drug therapy occurs following diagnosis by the prescriber; the ordering of laboratory tests; or other patient care management measures related to monitoring or improving the outcomes of drug or device therapy. No such collaborative agreement shall exceed the scope of practice of the respective parties. Any pharmacist who deviates from or practices in a manner inconsistent with the terms of a collaborative agreement shall be in violation of § 54.1-2902; such violation shall constitute grounds for disciplinary action pursuant to §§ 54.1-2400 and 54.1-3316.

Collaborative agreements may only be used for conditions which have protocols that are clinically accepted as the standard of care, or are approved by the Boards of Medicine and Pharmacy. The Boards of Medicine and Pharmacy shall jointly develop and promulgate regulations to implement the provisions of this section and to facilitate the development and implementation of safe and effective collaborative agreements between the appropriate practitioners and pharmacists. The regulations shall include guidelines concerning the use of protocols, and a procedure to allow for the approval or disapproval of specific protocols by the Boards of Medicine and Pharmacy if review is requested by a practitioner or pharmacist.

Nothing in this section shall be construed to supersede the provisions of § 54.1-3303.

§ 54.1-3301. Exceptions.

This chapter shall not be construed to:

1. Interfere with any legally qualified practitioner of dentistry, or veterinary medicine or any physician acting on behalf of the Virginia Department of Health or local health departments, in the compounding of his prescriptions or the purchase and possession of drugs as he may require;

2. Prevent any legally qualified practitioner of dentistry, or veterinary medicine or any prescriber, as defined in § 54.1-3401, acting on behalf of the Virginia Department of Health or local health departments, from administering or supplying to his patients the medicines that he deems proper under the conditions of § 54.1-3303 or from causing drugs to be administered or dispensed pursuant to §§ 32.1-42.1 and 54.1-3408, except that a veterinarian shall only be authorized to dispense a compounded drug, distributed from a pharmacy, when (i) the animal is his own patient, (ii) the animal is a companion animal as defined in regulations promulgated by the Board of Veterinary Medicine, (iii) the quantity dispensed is no more than a 72-hour supply, (iv) the compounded drug is for the treatment of an emergency condition, and (v) timely access to a compounding pharmacy is not available, as determined by the prescribing veterinarian;

3. Prohibit the sale by merchants and retail dealers of proprietary medicines as defined in Chapter 34 (§ 54.1-3400 et seq.) of this title;

4. Prevent the operation of automated drug dispensing systems in hospitals pursuant to Chapter 34 (§ 54.1-3400 et seq.) of this title;

5. Prohibit the employment of ancillary personnel to assist a pharmacist as provided in the regulations of the Board;

6. Interfere with any legally qualified practitioner of medicine, osteopathy, or podiatry from purchasing, possessing or administering controlled substances to his own patients or providing controlled substances to his own patients in a bona fide medical emergency or providing manufacturers' professional samples to his own patients;

7. Interfere with any legally qualified practitioner of optometry, certified or licensed to use diagnostic pharmaceutical agents, from purchasing, possessing or administering those controlled substances as specified in § 54.1-3221 or interfere with any legally qualified practitioner of optometry certified to

551 prescribe therapeutic pharmaceutical agents from purchasing, possessing, or administering to his own
552 patients those controlled substances as specified in § 54.1-3222 and the TPA formulary, providing
553 manufacturers' samples of these drugs to his own patients, or dispensing, administering, or selling
554 ophthalmic devices as authorized in § 54.1-3204;

555 8. Interfere with any physician assistant with prescriptive authority receiving and dispensing to his
556 own patients manufacturers' professional samples of controlled substances and devices that he is
557 authorized, in compliance with the provisions of § 54.1-2952.1, to prescribe according to his practice
558 setting and a written agreement with a physician or podiatrist;

559 9. Interfere with any licensed nurse practitioner with prescriptive authority receiving and dispensing
560 to his own patients manufacturers' professional samples of controlled substances and devices that he is
561 authorized, in compliance with the provisions of § 54.1-2957.01, to prescribe according to his practice
562 setting and a written or electronic agreement with a physician;

563 10. Interfere with any legally qualified practitioner of medicine or osteopathy participating in an
564 indigent patient program offered by a pharmaceutical manufacturer in which the practitioner sends a
565 prescription for one of his own patients to the manufacturer, and the manufacturer donates a stock bottle
566 of the prescription drug ordered at no cost to the practitioner or patient. The practitioner may dispense
567 such medication at no cost to the patient without holding a license to dispense from the Board of
568 Pharmacy. However, the container in which the drug is dispensed shall be labeled in accordance with
569 the requirements of § 54.1-3410, and, unless directed otherwise by the practitioner or the patient, shall
570 meet standards for special packaging as set forth in § 54.1-3426 and Board of Pharmacy regulations. In
571 lieu of dispensing directly to the patient, a practitioner may transfer the donated drug with a valid
572 prescription to a pharmacy for dispensing to the patient. The practitioner or pharmacy participating in
573 the program shall not use the donated drug for any purpose other than dispensing to the patient for
574 whom it was originally donated, except as authorized by the donating manufacturer for another patient
575 meeting that manufacturer's requirements for the indigent patient program. Neither the practitioner nor
576 the pharmacy shall charge the patient for any medication provided through a manufacturer's indigent
577 patient program pursuant to this subdivision. A participating pharmacy, including a pharmacy
578 participating in bulk donation programs, may charge a reasonable dispensing or administrative fee to
579 offset the cost of dispensing, not to exceed the actual costs of such dispensing. However, if the patient
580 is unable to pay such fee, the dispensing or administrative fee shall be waived;

581 11. Interfere with any legally qualified practitioner of medicine or osteopathy from providing
582 controlled substances to his own patients in a free clinic without charge when such controlled substances
583 are donated by an entity other than a pharmaceutical manufacturer as authorized by subdivision 10. The
584 practitioner shall first obtain a controlled substances registration from the Board and shall comply with
585 the labeling and packaging requirements of this chapter and the Board's regulations; or

586 12. Prevent any pharmacist from providing free health care to an underserved population in Virginia
587 who (i) does not regularly practice pharmacy in Virginia, (ii) holds a current valid license or certificate
588 to practice pharmacy in another state, territory, district or possession of the United States, (iii) volunteers
589 to provide free health care to an underserved area of this Commonwealth under the auspices of a
590 publicly supported all volunteer, nonprofit organization that sponsors the provision of health care to
591 populations of underserved people, (iv) files a copy of the license or certificate issued in such other
592 jurisdiction with the Board, (v) notifies the Board at least five business days prior to the voluntary
593 provision of services of the dates and location of such service, and (vi) acknowledges, in writing, that
594 such licensure exemption shall only be valid, in compliance with the Board's regulations, during the
595 limited period that such free health care is made available through the volunteer, nonprofit organization
596 on the dates and at the location filed with the Board. The Board may deny the right to practice in
597 Virginia to any pharmacist whose license has been previously suspended or revoked, who has been
598 convicted of a felony or who is otherwise found to be in violation of applicable laws or regulations.
599 However, the Board shall allow a pharmacist who meets the above criteria to provide volunteer services
600 without prior notice for a period of up to three days, provided the nonprofit organization verifies that the
601 practitioner has a valid, unrestricted license in another state; or

602 13. *Interfere with any licensed doctorate of medical science with prescriptive authority receiving and*
603 *dispensing to his own patients manufacturers' professional samples of controlled substances and devices*
604 *that he is authorized, in compliance with the provisions of § 54.1-2953.2, to prescribe according to his*
605 *practice setting and a written or electronic agreement with a physician.*

606 This section shall not be construed as exempting any person from the licensure, registration,
607 permitting and record keeping requirements of this chapter or Chapter 34 of this title.

608 **§ 54.1-3303. Prescriptions to be issued and drugs to be dispensed for medical or therapeutic**
609 **purposes only.**

610 A. A prescription for a controlled substance may be issued only by a practitioner of medicine,
611 osteopathy, podiatry, dentistry or veterinary medicine who is authorized to prescribe controlled
612 substances, or by a licensed nurse practitioner pursuant to § 54.1-2957.01, a licensed doctorate of

medical science pursuant to § 54.1-2953.3, a licensed physician assistant pursuant to § 54.1-2952.1, or a TPA-certified optometrist pursuant to Article 5 (§ 54.1-3222 et seq.) of Chapter 32. The prescription shall be issued for a medicinal or therapeutic purpose and may be issued only to persons or animals with whom the practitioner has a bona fide practitioner-patient relationship.

For purposes of this section, a bona fide practitioner-patient-pharmacist relationship is one in which a practitioner prescribes, and a pharmacist dispenses, controlled substances in good faith to his patient for a medicinal or therapeutic purpose within the course of his professional practice. In addition, a bona fide practitioner-patient relationship means that the practitioner shall (i) ensure that a medical or drug history is obtained; (ii) provide information to the patient about the benefits and risks of the drug being prescribed; (iii) perform or have performed an appropriate examination of the patient, either physically or by the use of instrumentation and diagnostic equipment through which images and medical records may be transmitted electronically; except for medical emergencies, the examination of the patient shall have been performed by the practitioner himself, within the group in which he practices, or by a consulting practitioner prior to issuing a prescription; and (iv) initiate additional interventions and follow-up care, if necessary, especially if a prescribed drug may have serious side effects. A practitioner who performs or has performed an appropriate examination of the patient required pursuant to clause (iii), either physically or by the use of instrumentation and diagnostic equipment through which images and medical records may be transmitted electronically, for the purpose of establishing a bona fide practitioner-patient relationship, may prescribe Schedule II through VI controlled substances to the patient, provided that the prescribing of such Schedule II through V controlled substance is in compliance with federal requirements for the practice of telemedicine.

For the purpose of prescribing a Schedule VI controlled substance to a patient via telemedicine services as defined in § 38.2-3418.16, a prescriber may establish a bona fide practitioner-patient relationship by an examination through face-to-face interactive, two-way, real-time communications services or store-and-forward technologies when all of the following conditions are met: (a) the patient has provided a medical history that is available for review by the prescriber; (b) the prescriber obtains an updated medical history at the time of prescribing; (c) the prescriber makes a diagnosis at the time of prescribing; (d) the prescriber conforms to the standard of care expected of in-person care as appropriate to the patient's age and presenting condition, including when the standard of care requires the use of diagnostic testing and performance of a physical examination, which may be carried out through the use of peripheral devices appropriate to the patient's condition; (e) the prescriber is actively licensed in the Commonwealth and authorized to prescribe; (f) if the patient is a member or enrollee of a health plan or carrier, the prescriber has been credentialed by the health plan or carrier as a participating provider and the diagnosing and prescribing meets the qualifications for reimbursement by the health plan or carrier pursuant to § 38.2-3418.16; and (g) upon request, the prescriber provides patient records in a timely manner in accordance with the provisions of § 32.1-127.1:03 and all other state and federal laws and regulations. Nothing in this paragraph shall permit a prescriber to establish a bona fide practitioner-patient relationship for the purpose of prescribing a Schedule VI controlled substance when the standard of care dictates that an in-person physical examination is necessary for diagnosis. Nothing in this paragraph shall apply to: (1) a prescriber providing on-call coverage per an agreement with another prescriber or his prescriber's professional entity or employer; (2) a prescriber consulting with another prescriber regarding a patient's care; or (3) orders of prescribers for hospital out-patients or in-patients.

Any practitioner who prescribes any controlled substance with the knowledge that the controlled substance will be used otherwise than medicinally or for therapeutic purposes shall be subject to the criminal penalties provided in § 18.2-248 for violations of the provisions of law relating to the distribution or possession of controlled substances.

B. In order to determine whether a prescription that appears questionable to the pharmacist results from a bona fide practitioner-patient relationship, the pharmacist shall contact the prescribing practitioner or his agent and verify the identity of the patient and name and quantity of the drug prescribed. The person knowingly filling an invalid prescription shall be subject to the criminal penalties provided in § 18.2-248 for violations of the provisions of law relating to the sale, distribution or possession of controlled substances.

No prescription shall be filled unless there is a bona fide practitioner-patient-pharmacist relationship. A prescription not issued in the usual course of treatment or for authorized research is not a valid prescription.

C. Notwithstanding any provision of law to the contrary and consistent with recommendations of the Centers for Disease Control and Prevention or the Department of Health, a practitioner may prescribe Schedule VI antibiotics and antiviral agents to other persons in close contact with a diagnosed patient when (i) the practitioner meets all requirements of a bona fide practitioner-patient relationship, as defined in subsection A, with the diagnosed patient; (ii) in the practitioner's professional judgment, the

practitioner deems there is urgency to begin treatment to prevent the transmission of a communicable disease; (iii) the practitioner has met all requirements of a bona fide practitioner-patient relationship, as defined in subsection A, for the close contact except for the physical examination required in clause (iii) of subsection A; and (iv) when such emergency treatment is necessary to prevent imminent risk of death, life-threatening illness, or serious disability.

D. A pharmacist may dispense a controlled substance pursuant to a prescription of an out-of-state practitioner of medicine, osteopathy, podiatry, dentistry, optometry, or veterinary medicine, a nurse practitioner, *a doctorate of medical science*, or a physician assistant authorized to issue such prescription if the prescription complies with the requirements of this chapter and the Drug Control Act (§ 54.1-3400 et seq.).

E. A licensed nurse practitioner who is authorized to prescribe controlled substances pursuant to § 54.1-2957.01 may issue prescriptions or provide manufacturers' professional samples for controlled substances and devices as set forth in the Drug Control Act (§ 54.1-3400 et seq.) in good faith to his patient for a medicinal or therapeutic purpose within the scope of his professional practice.

F. *A licensed doctorate of medical science who is authorized to prescribe controlled substances pursuant to § 54.1-2953.3 may issue prescriptions or provide manufacturers' professional samples for controlled substances and devices as set forth in the Drug Control Act (§ 54.1-3400 et seq.) in good faith to his patient for a medicinal or therapeutic purpose within the scope of his professional practice.*

G. A licensed physician assistant who is authorized to prescribe controlled substances pursuant to § 54.1-2952.1 may issue prescriptions or provide manufacturers' professional samples for controlled substances and devices as set forth in the Drug Control Act (§ 54.1-3400 et seq.) in good faith to his patient for a medicinal or therapeutic purpose within the scope of his professional practice.

~~G. H.~~ A TPA-certified optometrist who is authorized to prescribe controlled substances pursuant to Article 5 (§ 54.1-3222 et seq.) of Chapter 32 may issue prescriptions in good faith or provide manufacturers' professional samples to his patients for medicinal or therapeutic purposes within the scope of his professional practice for the drugs specified on the TPA-Formulary, established pursuant to § 54.1-3223, which shall be limited to (i) analgesics included on Schedule II controlled substances as defined in § 54.1-3448 of the Drug Control Act (§ 54.1-3400 et seq.) consisting of hydrocodone in combination with acetaminophen; (ii) oral analgesics included in Schedules III through VI, as defined in §§ 54.1-3450 and 54.1-3455 of the Drug Control Act (§ 54.1-3400 et seq.), which are appropriate to relieve ocular pain; (iii) other oral Schedule VI controlled substances, as defined in § 54.1-3455 of the Drug Control Act, appropriate to treat diseases and abnormal conditions of the human eye and its adnexa; (iv) topically applied Schedule VI drugs, as defined in § 54.1-3455 of the Drug Control Act; and (v) intramuscular administration of epinephrine for treatment of emergency cases of anaphylactic shock.

H. I. The requirement for a bona fide practitioner-patient relationship shall be deemed to be satisfied by a member or committee of a hospital's medical staff when approving a standing order or protocol for the administration of influenza vaccinations and pneumococcal vaccinations in a hospital in compliance with § 32.1-126.4.

§ 54.1-3401. (Effective until July 1, 2020) Definitions.

As used in this chapter, unless the context requires a different meaning:

"Administer" means the direct application of a controlled substance, whether by injection, inhalation, ingestion, or any other means, to the body of a patient or research subject by (i) a practitioner or by his authorized agent and under his direction or (ii) the patient or research subject at the direction and in the presence of the practitioner.

"Advertisement" means all representations disseminated in any manner or by any means, other than by labeling, for the purpose of inducing, or which are likely to induce, directly or indirectly, the purchase of drugs or devices.

"Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer, distributor, or dispenser. It does not include a common or contract carrier, public warehouseman, or employee of the carrier or warehouseman.

"Anabolic steroid" means any drug or hormonal substance, chemically and pharmacologically related to testosterone, other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone.

"Animal" means any nonhuman animate being endowed with the power of voluntary action.

"Automated drug dispensing system" means a mechanical or electronic system that performs operations or activities, other than compounding or administration, relating to pharmacy services, including the storage, dispensing, or distribution of drugs and the collection, control, and maintenance of all transaction information, to provide security and accountability for such drugs.

"Biological product" means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein other than a chemically synthesized polypeptide, or analogous product, or arsphenamine or any derivative of arsphenamine or any other trivalent organic arsenic compound, applicable to the prevention, treatment, or cure of a disease or condition of human

beings.

"Biosimilar" means a biological product that is highly similar to a specific reference biological product, notwithstanding minor differences in clinically inactive compounds, such that there are no clinically meaningful differences between the reference biological product and the biological product that has been licensed as a biosimilar pursuant to 42 U.S.C. § 262(k) in terms of safety, purity, and potency of the product.

"Board" means the Board of Pharmacy.

"Bulk drug substance" means any substance that is represented for use, and that, when used in the compounding, manufacturing, processing, or packaging of a drug, becomes an active ingredient or a finished dosage form of the drug; however, "bulk drug substance" shall not include intermediates that are used in the synthesis of such substances.

"Change of ownership" of an existing entity permitted, registered, or licensed by the Board means (i) the sale or transfer of all or substantially all of the assets of the entity or of any corporation that owns or controls the entity; (ii) the creation of a partnership by a sole proprietor, the dissolution of a partnership, or change in partnership composition; (iii) the acquisition or disposal of 50 percent or more of the outstanding shares of voting stock of a corporation owning the entity or of the parent corporation of a wholly owned subsidiary owning the entity, except that this shall not apply to any corporation the voting stock of which is actively traded on any securities exchange or in any over-the-counter market; (iv) the merger of a corporation owning the entity or of the parent corporation of a wholly-owned subsidiary owning the entity with another business or corporation; or (v) the expiration or forfeiture of a corporation's charter.

"Co-licensed partner" means a person who, with at least one other person, has the right to engage in the manufacturing or marketing of a prescription drug, consistent with state and federal law.

"Compounding" means the combining of two or more ingredients to fabricate such ingredients into a single preparation and includes the mixing, assembling, packaging, or labeling of a drug or device (i) by a pharmacist, or within a permitted pharmacy, pursuant to a valid prescription issued for a medicinal or therapeutic purpose in the context of a bona fide practitioner-patient-pharmacist relationship, or in expectation of receiving a valid prescription based on observed historical patterns of prescribing and dispensing; (ii) by a practitioner of medicine, osteopathy, podiatry, dentistry, or veterinary medicine as an incident to his administering or dispensing, if authorized to dispense, a controlled substance in the course of his professional practice; or (iii) for the purpose of, or as incident to, research, teaching, or chemical analysis and not for sale or for dispensing. The mixing, diluting, or reconstituting of a manufacturer's product drugs for the purpose of administration to a patient, when performed by a practitioner of medicine or osteopathy licensed under Chapter 29 (§ 54.1-2900 et seq.), a person supervised by such practitioner pursuant to subdivision A 6 or 19 of § 54.1-2901, or a person supervised by such practitioner or a licensed nurse practitioner, *doctorate of medical science*, or physician assistant pursuant to subdivision A 4 of § 54.1-2901 shall not be considered compounding.

"Controlled substance" means a drug, substance, or immediate precursor in Schedules I through VI of this chapter. The term shall not include distilled spirits, wine, malt beverages, or tobacco as those terms are defined or used in Title 3.2 or Title 4.1. The term "controlled substance" includes a controlled substance analog that has been placed into Schedule I or II by the Board pursuant to the regulatory authority in subsection D of § 54.1-3443.

"Controlled substance analog" means a substance the chemical structure of which is substantially similar to the chemical structure of a controlled substance in Schedule I or II and either (i) which has a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance in Schedule I or II or (ii) with respect to a particular person, which such person represents or intends to have a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance in Schedule I or II. "Controlled substance analog" does not include (a) any substance for which there is an approved new drug application as defined under § 505 of the federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355) or that is generally recognized as safe and effective pursuant to §§ 501, 502, and 503 of the federal Food, Drug, and Cosmetic Act (21 U.S.C. §§ 351, 352, and 353) and 21 C.F.R. Part 330; (b) with respect to a particular person, any substance for which an exemption is in effect for investigational use for that person under § 505 of the federal Food, Drug, and Cosmetic Act to the extent that the conduct with respect to that substance is pursuant to such exemption; or (c) any substance to the extent not intended for human consumption before such an exemption takes effect with respect to that substance.

"DEA" means the Drug Enforcement Administration, U.S. Department of Justice, or its successor agency.

"Deliver" or "delivery" means the actual, constructive, or attempted transfer of any item regulated by

797 this chapter, whether or not there exists an agency relationship.

798 "Device" means instruments, apparatus, and contrivances, including their components, parts, and
799 accessories, intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in
800 man or animals or to affect the structure or any function of the body of man or animals.

801 "Dialysis care technician" or "dialysis patient care technician" means an individual who is certified
802 by an organization approved by the Board of Health Professions pursuant to Chapter 27.01 (§
803 54.1-2729.1 et seq.) and who, under the supervision of a licensed physician, nurse practitioner, physician
804 assistant, or a registered nurse, assists in the care of patients undergoing renal dialysis treatments in a
805 Medicare-certified renal dialysis facility.

806 "Dialysis solution" means either the commercially available, unopened, sterile solutions whose
807 purpose is to be instilled into the peritoneal cavity during the medical procedure known as peritoneal
808 dialysis, or commercially available solutions whose purpose is to be used in the performance of
809 hemodialysis not to include any solutions administered to the patient intravenously.

810 "Dispense" means to deliver a drug to an ultimate user or research subject by or pursuant to the
811 lawful order of a practitioner, including the prescribing and administering, packaging, labeling, or
812 compounding necessary to prepare the substance for that delivery. However, dispensing shall not include
813 the transportation of drugs mixed, diluted, or reconstituted in accordance with this chapter to other sites
814 operated by such practitioner or that practitioner's medical practice for the purpose of administration of
815 such drugs to patients of the practitioner or that practitioner's medical practice at such other sites. For
816 practitioners of medicine or osteopathy, "dispense" shall only include the provision of drugs by a
817 practitioner to patients to take with them away from the practitioner's place of practice.

818 "Dispenser" means a practitioner who dispenses.

819 "Distribute" means to deliver other than by administering or dispensing a controlled substance.

820 "Distributor" means a person who distributes.

821 "Drug" means (i) articles or substances recognized in the official United States Pharmacopoeia
822 National Formulary or official Homeopathic Pharmacopoeia of the United States, or any supplement to
823 any of them; (ii) articles or substances intended for use in the diagnosis, cure, mitigation, treatment, or
824 prevention of disease in man or animals; (iii) articles or substances, other than food, intended to affect
825 the structure or any function of the body of man or animals; (iv) articles or substances intended for use
826 as a component of any article specified in clause (i), (ii), or (iii); or (v) a biological product. "Drug"
827 does not include devices or their components, parts, or accessories.

828 "Drug product" means a specific drug in dosage form from a known source of manufacture, whether
829 by brand or therapeutically equivalent drug product name.

830 "Electronic transmission prescription" means any prescription, other than an oral or written
831 prescription or a prescription transmitted by facsimile machine, that is electronically transmitted directly
832 to a pharmacy without interception or intervention from a third party from a practitioner authorized to
833 prescribe or from one pharmacy to another pharmacy.

834 "Facsimile (FAX) prescription" means a written prescription or order that is transmitted by an
835 electronic device over telephone lines that sends the exact image to the receiving pharmacy in hard copy
836 form.

837 "FDA" means the U.S. Food and Drug Administration.

838 "Hashish oil" means any oily extract containing one or more cannabinoids, but shall not include any
839 such extract with a tetrahydrocannabinol content of less than 12 percent by weight.

840 "Immediate precursor" means a substance which the Board of Pharmacy has found to be and by
841 regulation designates as being the principal compound commonly used or produced primarily for use,
842 and which is an immediate chemical intermediary used or likely to be used in the manufacture of a
843 controlled substance, the control of which is necessary to prevent, curtail, or limit manufacture.

844 "Interchangeable" means a biosimilar that meets safety standards for determining interchangeability
845 pursuant to 42 U.S.C. § 262(k)(4).

846 "Label" means a display of written, printed, or graphic matter upon the immediate container of any
847 article. A requirement made by or under authority of this chapter that any word, statement, or other
848 information appear on the label shall not be considered to be complied with unless such word,
849 statement, or other information also appears on the outside container or wrapper, if any, of the retail
850 package of such article or is easily legible through the outside container or wrapper.

851 "Labeling" means all labels and other written, printed, or graphic matter on an article or any of its
852 containers or wrappers, or accompanying such article.

853 "Manufacture" means the production, preparation, propagation, conversion, or processing of any item
854 regulated by this chapter, either directly or indirectly by extraction from substances of natural origin, or
855 independently by means of chemical synthesis, or by a combination of extraction and chemical
856 synthesis, and includes any packaging or repackaging of the substance or labeling or relabeling of its
857 container. This term does not include compounding.

858 "Manufacturer" means every person who manufactures, a manufacturer's co-licensed partner, or a

859 repackager.

860 "Marijuana" means any part of a plant of the genus *Cannabis* whether growing or not, its seeds, or
861 its resin; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its
862 seeds, or its resin. Marijuana shall not include any oily extract containing one or more cannabinoids
863 unless such extract contains less than 12 percent of tetrahydrocannabinol by weight, nor shall marijuana
864 include the mature stalks of such plant, fiber produced from such stalk, or oil or cake made from the
865 seeds of such plant, unless such stalks, fiber, oil, or cake is combined with other parts of plants of the
866 genus *Cannabis*. Marijuana shall not include industrial hemp as defined in § 3.2-4112 that is possessed,
867 cultivated, or manufactured by a grower licensed pursuant to § 3.2-4115.

868 "Medical equipment supplier" means any person, as defined in § 1-230, engaged in the delivery to
869 the ultimate consumer, pursuant to the lawful order of a practitioner, of hypodermic syringes and
870 needles, medicinal oxygen, Schedule VI controlled devices, those Schedule VI controlled substances with
871 no medicinal properties that are used for the operation and cleaning of medical equipment, solutions for
872 peritoneal dialysis, and sterile water or saline for irrigation.

873 "Narcotic drug" means any of the following, whether produced directly or indirectly by extraction
874 from substances of vegetable origin, or independently by means of chemical synthesis, or by a
875 combination of extraction and chemical synthesis: (i) opium, opiates, and any salt, compound, derivative,
876 or preparation of opium or opiates; (ii) any salt, compound, isomer, derivative, or preparation thereof
877 which is chemically equivalent or identical with any of the substances referred to in clause (i), but not
878 including the isoquinoline alkaloids of opium; (iii) opium poppy and poppy straw; (iv) coca leaves and
879 any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, isomer,
880 derivative, or preparation thereof which is chemically equivalent or identical with any of these
881 substances, but not including decocainized coca leaves or extraction of coca leaves which do not contain
882 cocaine or ecgonine.

883 "New drug" means (i) any drug, except a new animal drug or an animal feed bearing or containing a
884 new animal drug, the composition of which is such that such drug is not generally recognized, among
885 experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs,
886 as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling,
887 except that such a drug not so recognized shall not be deemed to be a "new drug" if at any time prior
888 to the enactment of this chapter it was subject to the Food and Drugs Act of June 30, 1906, as
889 amended, and if at such time its labeling contained the same representations concerning the conditions
890 of its use, or (ii) any drug, except a new animal drug or an animal feed bearing or containing a new
891 animal drug, the composition of which is such that such drug, as a result of investigations to determine
892 its safety and effectiveness for use under such conditions, has become so recognized, but which has not,
893 otherwise than in such investigations, been used to a material extent or for a material time under such
894 conditions.

895 "Nuclear medicine technologist" means an individual who holds a current certification with the
896 American Registry of Radiological Technologists or the Nuclear Medicine Technology Certification
897 Board.

898 "Official compendium" means the official United States Pharmacopoeia National Formulary, official
899 Homeopathic Pharmacopoeia of the United States, or any supplement to any of them.

900 "Official written order" means an order written on a form provided for that purpose by the U.S. Drug
901 Enforcement Administration, under any laws of the United States making provision therefor, if such
902 order forms are authorized and required by federal law, and if no such order form is provided then on
903 an official form provided for that purpose by the Board of Pharmacy.

904 "Opiate" means any substance having an addiction-forming or addiction-sustaining liability similar to
905 morphine or being capable of conversion into a drug having such addiction-forming or
906 addiction-sustaining liability. It does not include, unless specifically designated as controlled under
907 Article 4 (§ 54.1-3437 et seq.), the dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts
908 (dextrorothorphan). It does include its racemic and levorotatory forms.

909 "Opium poppy" means the plant of the species *Papaver somniferum* L., except the seeds thereof.

910 "Original package" means the unbroken container or wrapping in which any drug or medicine is
911 enclosed together with label and labeling, put up by or for the manufacturer, wholesaler, or distributor
912 for use in the delivery or display of such article.

913 "Outsourcing facility" means a facility that is engaged in the compounding of sterile drugs and is
914 currently registered as an outsourcing facility with the U.S. Secretary of Health and Human Services and
915 that complies with all applicable requirements of federal and state law, including the Federal Food,
916 Drug, and Cosmetic Act.

917 "Person" means both the plural and singular, as the case demands, and includes an individual,
918 partnership, corporation, association, governmental agency, trust, or other institution or entity.

919 "Pharmacist-in-charge" means the person who, being licensed as a pharmacist, signs the application

920 for a pharmacy permit and assumes full legal responsibility for the operation of the relevant pharmacy in
921 a manner complying with the laws and regulations for the practice of pharmacy and the sale and
922 dispensing of controlled substances; the "pharmacist-in-charge" shall personally supervise the pharmacy
923 and the pharmacy's personnel as required by § 54.1-3432.

924 "Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing.

925 "Practitioner" means a physician, dentist, licensed nurse practitioner pursuant to § 54.1-2957.01,
926 licensed physician assistant pursuant to § 54.1-2952.1, *licensed doctorate of medical science pursuant to*
927 *§ 54.1-2953.3*, pharmacist pursuant to § 54.1-3300, TPA-certified optometrist pursuant to Article 5
928 (§ 54.1-3222 et seq.) of Chapter 32, veterinarian, scientific investigator, or other person licensed,
929 registered, or otherwise permitted to distribute, dispense, prescribe and administer, or conduct research
930 with respect to a controlled substance in the course of professional practice or research in the
931 Commonwealth.

932 "Prescriber" means a practitioner who is authorized pursuant to §§ 54.1-3303 and 54.1-3408 to issue
933 a prescription.

934 "Prescription" means an order for drugs or medical supplies, written or signed or transmitted by word
935 of mouth, telephone, telegraph, or other means of communication to a pharmacist by a duly licensed
936 physician, dentist, veterinarian, or other practitioner authorized by law to prescribe and administer such
937 drugs or medical supplies.

938 "Prescription drug" means any drug required by federal law or regulation to be dispensed only
939 pursuant to a prescription, including finished dosage forms and active ingredients subject to § 503(b) of
940 the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 353(b)).

941 "Production" or "produce" includes the manufacture, planting, cultivation, growing, or harvesting of a
942 controlled substance or marijuana.

943 "Proprietary medicine" means a completely compounded nonprescription drug in its unbroken,
944 original package which does not contain any controlled substance or marijuana as defined in this chapter
945 and is not in itself poisonous, and which is sold, offered, promoted, or advertised directly to the general
946 public by or under the authority of the manufacturer or primary distributor, under a trademark, trade
947 name, or other trade symbol privately owned, and the labeling of which conforms to the requirements of
948 this chapter and applicable federal law. However, this definition shall not include a drug that is only
949 advertised or promoted professionally to licensed practitioners, a narcotic or drug containing a narcotic,
950 a drug that may be dispensed only upon prescription or the label of which bears substantially the
951 statement "Warning — may be habit-forming," or a drug intended for injection.

952 "Radiopharmaceutical" means any drug that exhibits spontaneous disintegration of unstable nuclei
953 with the emission of nuclear particles or photons and includes any non-radioactive reagent kit or
954 radionuclide generator that is intended to be used in the preparation of any such substance, but does not
955 include drugs such as carbon-containing compounds or potassium-containing salts that include trace
956 quantities of naturally occurring radionuclides. The term also includes any biological product that is
957 labeled with a radionuclide or intended solely to be labeled with a radionuclide.

958 "Reference biological product" means the single biological product licensed pursuant to 42 U.S.C.
959 § 262(a) against which a biological product is evaluated in an application submitted to the U.S. Food
960 and Drug Administration for licensure of biological products as biosimilar or interchangeable pursuant to
961 42 U.S.C. § 262(k).

962 "Sale" includes barter, exchange, or gift, or offer therefor, and each such transaction made by any
963 person, whether as an individual, proprietor, agent, servant, or employee.

964 "Therapeutically equivalent drug products" means drug products that contain the same active
965 ingredients and are identical in strength or concentration, dosage form, and route of administration and
966 that are classified as being therapeutically equivalent by the U.S. Food and Drug Administration
967 pursuant to the definition of "therapeutically equivalent drug products" set forth in the most recent
968 edition of the Approved Drug Products with Therapeutic Equivalence Evaluations, otherwise known as
969 the "Orange Book."

970 "Third-party logistics provider" means a person that provides or coordinates warehousing of or other
971 logistics services for a drug or device in interstate commerce on behalf of a manufacturer, wholesale
972 distributor, or dispenser of the drug or device but does not take ownership of the product or have
973 responsibility for directing the sale or disposition of the product.

974 "USP-NF" means the current edition of the United States Pharmacopeia-National Formulary.

975 "Warehouser" means any person, other than a wholesale distributor, manufacturer, or third-party
976 logistics provider, engaged in the business of selling or otherwise distributing prescription drugs or
977 devices to any person who is not the ultimate user or consumer. No person shall be subject to any state
978 or local tax by reason of this definition.

979 "Wholesale distribution" means distribution of prescription drugs to persons other than consumers or
980 patients, subject to the exemptions set forth in the federal Drug Supply Chain Security Act.

981 "Wholesale distributor" means any person other than a manufacturer, a manufacturer's co-licensed

partner, a third-party logistics provider, or a repackager that engages in wholesale distribution.

The words "drugs" and "devices" as used in Chapter 33 (§ 54.1-3300 et seq.) and in this chapter shall not include surgical or dental instruments, physical therapy equipment, X-ray apparatus, or glasses or lenses for the eyes.

The terms "pharmacist," "pharmacy," and "practice of pharmacy" as used in this chapter shall be defined as provided in Chapter 33 (§ 54.1-3300 et seq.) unless the context requires a different meaning.

§ 54.1-3401. (Effective July 1, 2020) Definitions.

As used in this chapter, unless the context requires a different meaning:

"Administer" means the direct application of a controlled substance, whether by injection, inhalation, ingestion, or any other means, to the body of a patient or research subject by (i) a practitioner or by his authorized agent and under his direction or (ii) the patient or research subject at the direction and in the presence of the practitioner.

"Advertisement" means all representations disseminated in any manner or by any means, other than by labeling, for the purpose of inducing, or which are likely to induce, directly or indirectly, the purchase of drugs or devices.

"Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer, distributor, or dispenser. It does not include a common or contract carrier, public warehouseman, or employee of the carrier or warehouseman.

"Anabolic steroid" means any drug or hormonal substance, chemically and pharmacologically related to testosterone, other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone.

"Animal" means any nonhuman animate being endowed with the power of voluntary action.

"Automated drug dispensing system" means a mechanical or electronic system that performs operations or activities, other than compounding or administration, relating to pharmacy services, including the storage, dispensing, or distribution of drugs and the collection, control, and maintenance of all transaction information, to provide security and accountability for such drugs.

"Biological product" means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein other than a chemically synthesized polypeptide, or analogous product, or arsphenamine or any derivative of arsphenamine or any other trivalent organic arsenic compound, applicable to the prevention, treatment, or cure of a disease or condition of human beings.

"Biosimilar" means a biological product that is highly similar to a specific reference biological product, notwithstanding minor differences in clinically inactive compounds, such that there are no clinically meaningful differences between the reference biological product and the biological product that has been licensed as a biosimilar pursuant to 42 U.S.C. § 262(k) in terms of safety, purity, and potency of the product.

"Board" means the Board of Pharmacy.

"Bulk drug substance" means any substance that is represented for use, and that, when used in the compounding, manufacturing, processing, or packaging of a drug, becomes an active ingredient or a finished dosage form of the drug; however, "bulk drug substance" shall not include intermediates that are used in the synthesis of such substances.

"Change of ownership" of an existing entity permitted, registered, or licensed by the Board means (i) the sale or transfer of all or substantially all of the assets of the entity or of any corporation that owns or controls the entity; (ii) the creation of a partnership by a sole proprietor, the dissolution of a partnership, or change in partnership composition; (iii) the acquisition or disposal of 50 percent or more of the outstanding shares of voting stock of a corporation owning the entity or of the parent corporation of a wholly owned subsidiary owning the entity, except that this shall not apply to any corporation the voting stock of which is actively traded on any securities exchange or in any over-the-counter market; (iv) the merger of a corporation owning the entity or of the parent corporation of a wholly-owned subsidiary owning the entity with another business or corporation; or (v) the expiration or forfeiture of a corporation's charter.

"Co-licensed partner" means a person who, with at least one other person, has the right to engage in the manufacturing or marketing of a prescription drug, consistent with state and federal law.

"Compounding" means the combining of two or more ingredients to fabricate such ingredients into a single preparation and includes the mixing, assembling, packaging, or labeling of a drug or device (i) by a pharmacist, or within a permitted pharmacy, pursuant to a valid prescription issued for a medicinal or therapeutic purpose in the context of a bona fide practitioner-patient-pharmacist relationship, or in expectation of receiving a valid prescription based on observed historical patterns of prescribing and dispensing; (ii) by a practitioner of medicine, osteopathy, podiatry, dentistry, or veterinary medicine as an incident to his administering or dispensing, if authorized to dispense, a controlled substance in the course of his professional practice; or (iii) for the purpose of, or as incident to, research, teaching, or chemical analysis and not for sale or for dispensing. The mixing, diluting, or reconstituting of a

1043 manufacturer's product drugs for the purpose of administration to a patient, when performed by a
1044 practitioner of medicine or osteopathy licensed under Chapter 29 (§ 54.1-2900 et seq.), a person
1045 supervised by such practitioner pursuant to subdivision A 6 or 19 of § 54.1-2901, or a person
1046 supervised by such practitioner or a licensed nurse practitioner, *doctorate of medical science*, or
1047 physician assistant pursuant to subdivision A 4 of § 54.1-2901 shall not be considered compounding.

1048 "Controlled substance" means a drug, substance, or immediate precursor in Schedules I through VI of
1049 this chapter. The term shall not include distilled spirits, wine, malt beverages, or tobacco as those terms
1050 are defined or used in Title 3.2 or Title 4.1. The term "controlled substance" includes a controlled
1051 substance analog that has been placed into Schedule I or II by the Board pursuant to the regulatory
1052 authority in subsection D of § 54.1-3443.

1053 "Controlled substance analog" means a substance the chemical structure of which is substantially
1054 similar to the chemical structure of a controlled substance in Schedule I or II and either (i) which has a
1055 stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar
1056 to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a
1057 controlled substance in Schedule I or II or (ii) with respect to a particular person, which such person
1058 represents or intends to have a stimulant, depressant, or hallucinogenic effect on the central nervous
1059 system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect
1060 on the central nervous system of a controlled substance in Schedule I or II. "Controlled substance
1061 analog" does not include (a) any substance for which there is an approved new drug application as
1062 defined under § 505 of the federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355) or that is generally
1063 recognized as safe and effective pursuant to §§ 501, 502, and 503 of the federal Food, Drug, and
1064 Cosmetic Act (21 U.S.C. §§ 351, 352, and 353) and 21 C.F.R. Part 330; (b) with respect to a particular
1065 person, any substance for which an exemption is in effect for investigational use for that person under
1066 § 505 of the federal Food, Drug, and Cosmetic Act to the extent that the conduct with respect to that
1067 substance is pursuant to such exemption; or (c) any substance to the extent not intended for human
1068 consumption before such an exemption takes effect with respect to that substance.

1069 "DEA" means the Drug Enforcement Administration, U.S. Department of Justice, or its successor
1070 agency.

1071 "Deliver" or "delivery" means the actual, constructive, or attempted transfer of any item regulated by
1072 this chapter, whether or not there exists an agency relationship.

1073 "Device" means instruments, apparatus, and contrivances, including their components, parts, and
1074 accessories, intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in
1075 man or animals or to affect the structure or any function of the body of man or animals.

1076 "Dialysis care technician" or "dialysis patient care technician" means an individual who is certified
1077 by an organization approved by the Board of Health Professions pursuant to Chapter 27.01 (§
1078 54.1-2729.1 et seq.) and who, under the supervision of a licensed physician, nurse practitioner, physician
1079 assistant, or a registered nurse, assists in the care of patients undergoing renal dialysis treatments in a
1080 Medicare-certified renal dialysis facility.

1081 "Dialysis solution" means either the commercially available, unopened, sterile solutions whose
1082 purpose is to be instilled into the peritoneal cavity during the medical procedure known as peritoneal
1083 dialysis, or commercially available solutions whose purpose is to be used in the performance of
1084 hemodialysis not to include any solutions administered to the patient intravenously.

1085 "Dispense" means to deliver a drug to an ultimate user or research subject by or pursuant to the
1086 lawful order of a practitioner, including the prescribing and administering, packaging, labeling, or
1087 compounding necessary to prepare the substance for that delivery. However, dispensing shall not include
1088 the transportation of drugs mixed, diluted, or reconstituted in accordance with this chapter to other sites
1089 operated by such practitioner or that practitioner's medical practice for the purpose of administration of
1090 such drugs to patients of the practitioner or that practitioner's medical practice at such other sites. For
1091 practitioners of medicine or osteopathy, "dispense" shall only include the provision of drugs by a
1092 practitioner to patients to take with them away from the practitioner's place of practice.

1093 "Dispenser" means a practitioner who dispenses.

1094 "Distribute" means to deliver other than by administering or dispensing a controlled substance.

1095 "Distributor" means a person who distributes.

1096 "Drug" means (i) articles or substances recognized in the official United States Pharmacopoeia
1097 National Formulary or official Homeopathic Pharmacopoeia of the United States, or any supplement to
1098 any of them; (ii) articles or substances intended for use in the diagnosis, cure, mitigation, treatment, or
1099 prevention of disease in man or animals; (iii) articles or substances, other than food, intended to affect
1100 the structure or any function of the body of man or animals; (iv) articles or substances intended for use
1101 as a component of any article specified in clause (i), (ii), or (iii); or (v) a biological product. "Drug"
1102 does not include devices or their components, parts, or accessories.

1103 "Drug product" means a specific drug in dosage form from a known source of manufacture, whether
1104 by brand or therapeutically equivalent drug product name.

"Electronic prescription" means a written prescription that is generated on an electronic application and is transmitted to a pharmacy as an electronic data file; Schedule II through V prescriptions shall be transmitted in accordance with 21 C.F.R. Part 1300.

"Facsimile (FAX) prescription" means a written prescription or order that is transmitted by an electronic device over telephone lines that sends the exact image to the receiving pharmacy in hard copy form.

"FDA" means the U.S. Food and Drug Administration.

"Hashish oil" means any oily extract containing one or more cannabinoids, but shall not include any such extract with a tetrahydrocannabinol content of less than 12 percent by weight.

"Immediate precursor" means a substance which the Board of Pharmacy has found to be and by regulation designates as being the principal compound commonly used or produced primarily for use, and which is an immediate chemical intermediary used or likely to be used in the manufacture of a controlled substance, the control of which is necessary to prevent, curtail, or limit manufacture.

"Interchangeable" means a biosimilar that meets safety standards for determining interchangeability pursuant to 42 U.S.C. § 262(k)(4).

"Label" means a display of written, printed, or graphic matter upon the immediate container of any article. A requirement made by or under authority of this chapter that any word, statement, or other information appear on the label shall not be considered to be complied with unless such word, statement, or other information also appears on the outside container or wrapper, if any, of the retail package of such article or is easily legible through the outside container or wrapper.

"Labeling" means all labels and other written, printed, or graphic matter on an article or any of its containers or wrappers, or accompanying such article.

"Manufacture" means the production, preparation, propagation, conversion, or processing of any item regulated by this chapter, either directly or indirectly by extraction from substances of natural origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis, and includes any packaging or repackaging of the substance or labeling or relabeling of its container. This term does not include compounding.

"Manufacturer" means every person who manufactures, a manufacturer's co-licensed partner, or a repackager.

"Marijuana" means any part of a plant of the genus *Cannabis* whether growing or not, its seeds, or its resin; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds, or its resin. Marijuana shall not include any oily extract containing one or more cannabinoids unless such extract contains less than 12 percent of tetrahydrocannabinol by weight, nor shall marijuana include the mature stalks of such plant, fiber produced from such stalk, or oil or cake made from the seeds of such plant, unless such stalks, fiber, oil, or cake is combined with other parts of plants of the genus *Cannabis*. Marijuana shall not include industrial hemp as defined in § 3.2-4112 that is possessed, cultivated, or manufactured by a grower licensed pursuant to § 3.2-4115.

"Medical equipment supplier" means any person, as defined in § 1-230, engaged in the delivery to the ultimate consumer, pursuant to the lawful order of a practitioner, of hypodermic syringes and needles, medicinal oxygen, Schedule VI controlled devices, those Schedule VI controlled substances with no medicinal properties that are used for the operation and cleaning of medical equipment, solutions for peritoneal dialysis, and sterile water or saline for irrigation.

"Narcotic drug" means any of the following, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (i) opium, opiates, and any salt, compound, derivative, or preparation of opium or opiates; (ii) any salt, compound, isomer, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in clause (i), but not including the isoquinoline alkaloids of opium; (iii) opium poppy and poppy straw; (iv) coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, isomer, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extraction of coca leaves which do not contain cocaine or ecgonine.

"New drug" means (i) any drug, except a new animal drug or an animal feed bearing or containing a new animal drug, the composition of which is such that such drug is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling, except that such a drug not so recognized shall not be deemed to be a "new drug" if at any time prior to the enactment of this chapter it was subject to the Food and Drugs Act of June 30, 1906, as amended, and if at such time its labeling contained the same representations concerning the conditions of its use, or (ii) any drug, except a new animal drug or an animal feed bearing or containing a new animal drug, the composition of which is such that such drug, as a result of investigations to determine

1166 its safety and effectiveness for use under such conditions, has become so recognized, but which has not,
1167 otherwise than in such investigations, been used to a material extent or for a material time under such
1168 conditions.

1169 "Nuclear medicine technologist" means an individual who holds a current certification with the
1170 American Registry of Radiological Technologists or the Nuclear Medicine Technology Certification
1171 Board.

1172 "Official compendium" means the official United States Pharmacopoeia National Formulary, official
1173 Homeopathic Pharmacopoeia of the United States, or any supplement to any of them.

1174 "Official written order" means an order written on a form provided for that purpose by the U.S. Drug
1175 Enforcement Administration, under any laws of the United States making provision therefor, if such
1176 order forms are authorized and required by federal law, and if no such order form is provided then on
1177 an official form provided for that purpose by the Board of Pharmacy.

1178 "Opiate" means any substance having an addiction-forming or addiction-sustaining liability similar to
1179 morphine or being capable of conversion into a drug having such addiction-forming or
1180 addiction-sustaining liability. It does not include, unless specifically designated as controlled under
1181 Article 4 (§ 54.1-3437 et seq.), the dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts
1182 (dextromethorphan). It does include its racemic and levorotatory forms.

1183 "Opium poppy" means the plant of the species *Papaver somniferum* L., except the seeds thereof.

1184 "Original package" means the unbroken container or wrapping in which any drug or medicine is
1185 enclosed together with label and labeling, put up by or for the manufacturer, wholesaler, or distributor
1186 for use in the delivery or display of such article.

1187 "Outsourcing facility" means a facility that is engaged in the compounding of sterile drugs and is
1188 currently registered as an outsourcing facility with the U.S. Secretary of Health and Human Services and
1189 that complies with all applicable requirements of federal and state law, including the Federal Food,
1190 Drug, and Cosmetic Act.

1191 "Person" means both the plural and singular, as the case demands, and includes an individual,
1192 partnership, corporation, association, governmental agency, trust, or other institution or entity.

1193 "Pharmacist-in-charge" means the person who, being licensed as a pharmacist, signs the application
1194 for a pharmacy permit and assumes full legal responsibility for the operation of the relevant pharmacy in
1195 a manner complying with the laws and regulations for the practice of pharmacy and the sale and
1196 dispensing of controlled substances; the "pharmacist-in-charge" shall personally supervise the pharmacy
1197 and the pharmacy's personnel as required by § 54.1-3432.

1198 "Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing.

1199 "Practitioner" means a physician, dentist, licensed nurse practitioner pursuant to § 54.1-2957.01,
1200 *licensed doctorate of medical science pursuant to § 54.1-2953.3*, licensed physician assistant pursuant to
1201 § 54.1-2952.1, pharmacist pursuant to § 54.1-3300, TPA-certified optometrist pursuant to Article 5
1202 (§ 54.1-3222 et seq.) of Chapter 32, veterinarian, scientific investigator, or other person licensed,
1203 registered, or otherwise permitted to distribute, dispense, prescribe and administer, or conduct research
1204 with respect to a controlled substance in the course of professional practice or research in the
1205 Commonwealth.

1206 "Prescriber" means a practitioner who is authorized pursuant to §§ 54.1-3303 and 54.1-3408 to issue
1207 a prescription.

1208 "Prescription" means an order for drugs or medical supplies, written or signed or transmitted by word
1209 of mouth, telephone, telegraph, or other means of communication to a pharmacist by a duly licensed
1210 physician, dentist, veterinarian, or other practitioner authorized by law to prescribe and administer such
1211 drugs or medical supplies.

1212 "Prescription drug" means any drug required by federal law or regulation to be dispensed only
1213 pursuant to a prescription, including finished dosage forms and active ingredients subject to § 503(b) of
1214 the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 353(b)).

1215 "Production" or "produce" includes the manufacture, planting, cultivation, growing, or harvesting of a
1216 controlled substance or marijuana.

1217 "Proprietary medicine" means a completely compounded nonprescription drug in its unbroken,
1218 original package which does not contain any controlled substance or marijuana as defined in this chapter
1219 and is not in itself poisonous, and which is sold, offered, promoted, or advertised directly to the general
1220 public by or under the authority of the manufacturer or primary distributor, under a trademark, trade
1221 name, or other trade symbol privately owned, and the labeling of which conforms to the requirements of
1222 this chapter and applicable federal law. However, this definition shall not include a drug that is only
1223 advertised or promoted professionally to licensed practitioners, a narcotic or drug containing a narcotic,
1224 a drug that may be dispensed only upon prescription or the label of which bears substantially the
1225 statement "Warning — may be habit-forming," or a drug intended for injection.

1226 "Radiopharmaceutical" means any drug that exhibits spontaneous disintegration of unstable nuclei
1227 with the emission of nuclear particles or photons and includes any non-radioactive reagent kit or

radionuclide generator that is intended to be used in the preparation of any such substance, but does not include drugs such as carbon-containing compounds or potassium-containing salts that include trace quantities of naturally occurring radionuclides. The term also includes any biological product that is labeled with a radionuclide or intended solely to be labeled with a radionuclide.

"Reference biological product" means the single biological product licensed pursuant to 42 U.S.C. § 262(a) against which a biological product is evaluated in an application submitted to the U.S. Food and Drug Administration for licensure of biological products as biosimilar or interchangeable pursuant to 42 U.S.C. § 262(k).

"Sale" includes barter, exchange, or gift, or offer therefor, and each such transaction made by any person, whether as an individual, proprietor, agent, servant, or employee.

"Therapeutically equivalent drug products" means drug products that contain the same active ingredients and are identical in strength or concentration, dosage form, and route of administration and that are classified as being therapeutically equivalent by the U.S. Food and Drug Administration pursuant to the definition of "therapeutically equivalent drug products" set forth in the most recent edition of the Approved Drug Products with Therapeutic Equivalence Evaluations, otherwise known as the "Orange Book."

"Third-party logistics provider" means a person that provides or coordinates warehousing of or other logistics services for a drug or device in interstate commerce on behalf of a manufacturer, wholesale distributor, or dispenser of the drug or device but does not take ownership of the product or have responsibility for directing the sale or disposition of the product.

"USP-NF" means the current edition of the United States Pharmacopeia-National Formulary.

"Warehouser" means any person, other than a wholesale distributor, manufacturer, or third-party logistics provider, engaged in the business of selling or otherwise distributing prescription drugs or devices to any person who is not the ultimate user or consumer. No person shall be subject to any state or local tax by reason of this definition.

"Wholesale distribution" means distribution of prescription drugs to persons other than consumers or patients, subject to the exemptions set forth in the federal Drug Supply Chain Security Act.

"Wholesale distributor" means any person other than a manufacturer, a manufacturer's co-licensed partner, a third-party logistics provider, or a repackager that engages in wholesale distribution.

The words "drugs" and "devices" as used in Chapter 33 (§ 54.1-3300 et seq.) and in this chapter shall not include surgical or dental instruments, physical therapy equipment, X-ray apparatus, or glasses or lenses for the eyes.

The terms "pharmacist," "pharmacy," and "practice of pharmacy" as used in this chapter shall be defined as provided in Chapter 33 (§ 54.1-3300 et seq.) unless the context requires a different meaning.

§ 54.1-3408. Professional use by practitioners.

A. A practitioner of medicine, osteopathy, podiatry, dentistry, or veterinary medicine or a licensed nurse practitioner pursuant to § 54.1-2957.01, *a licensed doctorate of medical science pursuant to § 54.1-2953.3*, a licensed physician assistant pursuant to § 54.1-2952.1, or a TPA-certified optometrist pursuant to Article 5 (§ 54.1-3222 et seq.) of Chapter 32 shall only prescribe, dispense, or administer controlled substances in good faith for medicinal or therapeutic purposes within the course of his professional practice.

B. The prescribing practitioner's order may be on a written prescription or pursuant to an oral prescription as authorized by this chapter. The prescriber may administer drugs and devices, or he may cause drugs or devices to be administered by:

1. A nurse, physician assistant, or intern under his direction and supervision;
2. Persons trained to administer drugs and devices to patients in state-owned or state-operated hospitals or facilities licensed as hospitals by the Board of Health or psychiatric hospitals licensed by the Department of Behavioral Health and Developmental Services who administer drugs under the control and supervision of the prescriber or a pharmacist;
3. Emergency medical services personnel certified and authorized to administer drugs and devices pursuant to regulations of the Board of Health who act within the scope of such certification and pursuant to an oral or written order or standing protocol; or
4. A licensed respiratory therapist as defined in § 54.1-2954 who administers by inhalation controlled substances used in inhalation or respiratory therapy.

C. Pursuant to an oral or written order or standing protocol, the prescriber, who is authorized by state or federal law to possess and administer radiopharmaceuticals in the scope of his practice, may authorize a nuclear medicine technologist to administer, under his supervision, radiopharmaceuticals used in the diagnosis or treatment of disease.

D. Pursuant to an oral or written order or standing protocol issued by the prescriber within the course of his professional practice, such prescriber may authorize registered nurses and licensed practical nurses to possess (i) epinephrine and oxygen for administration in treatment of emergency medical

1289 conditions and (ii) heparin and sterile normal saline to use for the maintenance of intravenous access
1290 lines.

1291 Pursuant to the regulations of the Board of Health, certain emergency medical services technicians
1292 may possess and administer epinephrine in emergency cases of anaphylactic shock.

1293 Pursuant to an order or standing protocol issued by the prescriber within the course of his
1294 professional practice, any school nurse, school board employee, employee of a local governing body, or
1295 employee of a local health department who is authorized by a prescriber and trained in the
1296 administration of epinephrine may possess and administer epinephrine.

1297 Pursuant to an order or a standing protocol issued by the prescriber within the course of his
1298 professional practice, any employee of a school for students with disabilities, as defined in § 22.1-319
1299 and licensed by the Board of Education, or any employee of a private school that is accredited pursuant
1300 to § 22.1-19 as administered by the Virginia Council for Private Education who is authorized by a
1301 prescriber and trained in the administration of epinephrine may possess and administer epinephrine.

1302 Pursuant to an order or a standing protocol issued by the prescriber within the course of his
1303 professional practice, any employee of a public institution of higher education or a private institution of
1304 higher education who is authorized by a prescriber and trained in the administration of epinephrine may
1305 possess and administer epinephrine.

1306 Pursuant to an order issued by the prescriber within the course of his professional practice, an
1307 employee of a provider licensed by the Department of Behavioral Health and Developmental Services or
1308 a person providing services pursuant to a contract with a provider licensed by the Department of
1309 Behavioral Health and Developmental Services may possess and administer epinephrine, provided such
1310 person is authorized and trained in the administration of epinephrine.

1311 Pursuant to an oral or written order or standing protocol issued by the prescriber within the course of
1312 his professional practice, such prescriber may authorize pharmacists to possess epinephrine and oxygen
1313 for administration in treatment of emergency medical conditions.

1314 E. Pursuant to an oral or written order or standing protocol issued by the prescriber within the course
1315 of his professional practice, such prescriber may authorize licensed physical therapists to possess and
1316 administer topical corticosteroids, topical lidocaine, and any other Schedule VI topical drug.

1317 F. Pursuant to an oral or written order or standing protocol issued by the prescriber within the course
1318 of his professional practice, such prescriber may authorize licensed athletic trainers to possess and
1319 administer topical corticosteroids, topical lidocaine, or other Schedule VI topical drugs; oxygen for use
1320 in emergency situations; and epinephrine for use in emergency cases of anaphylactic shock.

1321 G. Pursuant to an oral or written order or standing protocol issued by the prescriber within the
1322 course of his professional practice, and in accordance with policies and guidelines established by the
1323 Department of Health pursuant to § 32.1-50.2, such prescriber may authorize registered nurses or
1324 licensed practical nurses under the supervision of a registered nurse to possess and administer tuberculin
1325 purified protein derivative (PPD) in the absence of a prescriber. The Department of Health's policies and
1326 guidelines shall be consistent with applicable guidelines developed by the Centers for Disease Control
1327 and Prevention for preventing transmission of mycobacterium tuberculosis and shall be updated to
1328 incorporate any subsequently implemented standards of the Occupational Safety and Health
1329 Administration and the Department of Labor and Industry to the extent that they are inconsistent with
1330 the Department of Health's policies and guidelines. Such standing protocols shall explicitly describe the
1331 categories of persons to whom the tuberculin test is to be administered and shall provide for appropriate
1332 medical evaluation of those in whom the test is positive. The prescriber shall ensure that the nurse
1333 implementing such standing protocols has received adequate training in the practice and principles
1334 underlying tuberculin screening.

1335 The Health Commissioner or his designee may authorize registered nurses, acting as agents of the
1336 Department of Health, to possess and administer, at the nurse's discretion, tuberculin purified protein
1337 derivative (PPD) to those persons in whom tuberculin skin testing is indicated based on protocols and
1338 policies established by the Department of Health.

1339 H. Pursuant to a written order or standing protocol issued by the prescriber within the course of his
1340 professional practice, such prescriber may authorize, with the consent of the parents as defined in
1341 § 22.1-1, an employee of (i) a school board, (ii) a school for students with disabilities as defined in
1342 § 22.1-319 licensed by the Board of Education, or (iii) a private school accredited pursuant to § 22.1-19
1343 as administered by the Virginia Council for Private Education who is trained in the administration of
1344 insulin and glucagon to assist with the administration of insulin or administer glucagon to a student
1345 diagnosed as having diabetes and who requires insulin injections during the school day or for whom
1346 glucagon has been prescribed for the emergency treatment of hypoglycemia. Such authorization shall
1347 only be effective when a licensed nurse, nurse practitioner, physician, or physician assistant is not
1348 present to perform the administration of the medication.

1349 Pursuant to a written order or standing protocol issued by the prescriber within the course of his
1350 professional practice, such prescriber may authorize an employee of a public institution of higher

education or a private institution of higher education who is trained in the administration of insulin and glucagon to assist with the administration of insulin or administration of glucagon to a student diagnosed as having diabetes and who requires insulin injections or for whom glucagon has been prescribed for the emergency treatment of hypoglycemia. Such authorization shall only be effective when a licensed nurse, nurse practitioner, physician, or physician assistant is not present to perform the administration of the medication.

Pursuant to a written order issued by the prescriber within the course of his professional practice, such prescriber may authorize an employee of a provider licensed by the Department of Behavioral Health and Developmental Services or a person providing services pursuant to a contract with a provider licensed by the Department of Behavioral Health and Developmental Services to assist with the administration of insulin or to administer glucagon to a person diagnosed as having diabetes and who requires insulin injections or for whom glucagon has been prescribed for the emergency treatment of hypoglycemia, provided such employee or person providing services has been trained in the administration of insulin and glucagon.

I. A prescriber may authorize, pursuant to a protocol approved by the Board of Nursing, the administration of vaccines to adults for immunization, when a practitioner with prescriptive authority is not physically present, by (i) licensed pharmacists, (ii) registered nurses, or (iii) licensed practical nurses under the supervision of a registered nurse. A prescriber acting on behalf of and in accordance with established protocols of the Department of Health may authorize the administration of vaccines to any person by a pharmacist, nurse, or designated emergency medical services provider who holds an advanced life support certificate issued by the Commissioner of Health under the direction of an operational medical director when the prescriber is not physically present. The emergency medical services provider shall provide documentation of the vaccines to be recorded in the Virginia Immunization Information System.

J. A dentist may cause Schedule VI topical drugs to be administered under his direction and supervision by either a dental hygienist or by an authorized agent of the dentist.

Further, pursuant to a written order and in accordance with a standing protocol issued by the dentist in the course of his professional practice, a dentist may authorize a dental hygienist under his general supervision, as defined in § 54.1-2722, to possess and administer topical oral fluorides, topical oral anesthetics, topical and directly applied antimicrobial agents for treatment of periodontal pocket lesions, as well as any other Schedule VI topical drug approved by the Board of Dentistry.

In addition, a dentist may authorize a dental hygienist under his direction to administer Schedule VI nitrous oxide and oxygen inhalation analgesia and, to persons 18 years of age or older, Schedule VI local anesthesia.

K. Pursuant to an oral or written order or standing protocol issued by the prescriber within the course of his professional practice, such prescriber may authorize registered professional nurses certified as sexual assault nurse examiners-A (SANE-A) under his supervision and when he is not physically present to possess and administer preventive medications for victims of sexual assault as recommended by the Centers for Disease Control and Prevention.

L. This section shall not prevent the administration of drugs by a person who has satisfactorily completed a training program for this purpose approved by the Board of Nursing and who administers such drugs in accordance with a prescriber's instructions pertaining to dosage, frequency, and manner of administration, and in accordance with regulations promulgated by the Board of Pharmacy relating to security and record keeping, when the drugs administered would be normally self-administered by (i) an individual receiving services in a program licensed by the Department of Behavioral Health and Developmental Services; (ii) a resident of the Virginia Rehabilitation Center for the Blind and Vision Impaired; (iii) a resident of a facility approved by the Board or Department of Juvenile Justice for the placement of children in need of services or delinquent or alleged delinquent youth; (iv) a program participant of an adult day-care center licensed by the Department of Social Services; (v) a resident of any facility authorized or operated by a state or local government whose primary purpose is not to provide health care services; (vi) a resident of a private children's residential facility, as defined in § 63.2-100 and licensed by the Department of Social Services, Department of Education, or Department of Behavioral Health and Developmental Services; or (vii) a student in a school for students with disabilities, as defined in § 22.1-319 and licensed by the Board of Education.

In addition, this section shall not prevent a person who has successfully completed a training program for the administration of drugs via percutaneous gastrostomy tube approved by the Board of Nursing and been evaluated by a registered nurse as having demonstrated competency in administration of drugs via percutaneous gastrostomy tube from administering drugs to a person receiving services from a program licensed by the Department of Behavioral Health and Developmental Services to such person via percutaneous gastrostomy tube. The continued competency of a person to administer drugs via percutaneous gastrostomy tube shall be evaluated semiannually by a registered nurse.

1412 M. Medication aides registered by the Board of Nursing pursuant to Article 7 (§ 54.1-3041 et seq.)
1413 of Chapter 30 may administer drugs that would otherwise be self-administered to residents of any
1414 assisted living facility licensed by the Department of Social Services. A registered medication aide shall
1415 administer drugs pursuant to this section in accordance with the prescriber's instructions pertaining to
1416 dosage, frequency, and manner of administration; in accordance with regulations promulgated by the
1417 Board of Pharmacy relating to security and recordkeeping; in accordance with the assisted living
1418 facility's Medication Management Plan; and in accordance with such other regulations governing their
1419 practice promulgated by the Board of Nursing.

1420 N. In addition, this section shall not prevent the administration of drugs by a person who administers
1421 such drugs in accordance with a physician's instructions pertaining to dosage, frequency, and manner of
1422 administration and with written authorization of a parent, and in accordance with school board
1423 regulations relating to training, security and record keeping, when the drugs administered would be
1424 normally self-administered by a student of a Virginia public school. Training for such persons shall be
1425 accomplished through a program approved by the local school boards, in consultation with the local
1426 departments of health.

1427 O. In addition, this section shall not prevent the administration of drugs by a person to (i) a child in
1428 a child day program as defined in § 63.2-100 and regulated by the State Board of Social Services or a
1429 local government pursuant to § 15.2-914, or (ii) a student of a private school that is accredited pursuant
1430 to § 22.1-19 as administered by the Virginia Council for Private Education, provided such person (a) has
1431 satisfactorily completed a training program for this purpose approved by the Board of Nursing and
1432 taught by a registered nurse, licensed practical nurse, nurse practitioner, physician assistant, doctor of
1433 medicine or osteopathic medicine, or pharmacist; (b) has obtained written authorization from a parent or
1434 guardian; (c) administers drugs only to the child identified on the prescription label in accordance with
1435 the prescriber's instructions pertaining to dosage, frequency, and manner of administration; and (d)
1436 administers only those drugs that were dispensed from a pharmacy and maintained in the original,
1437 labeled container that would normally be self-administered by the child or student, or administered by a
1438 parent or guardian to the child or student.

1439 P. In addition, this section shall not prevent the administration or dispensing of drugs and devices by
1440 persons if they are authorized by the State Health Commissioner in accordance with protocols
1441 established by the State Health Commissioner pursuant to § 32.1-42.1 when (i) the Governor has
1442 declared a disaster or a state of emergency or the United States Secretary of Health and Human Services
1443 has issued a declaration of an actual or potential bioterrorism incident or other actual or potential public
1444 health emergency; (ii) it is necessary to permit the provision of needed drugs or devices; and (iii) such
1445 persons have received the training necessary to safely administer or dispense the needed drugs or
1446 devices. Such persons shall administer or dispense all drugs or devices under the direction, control, and
1447 supervision of the State Health Commissioner.

1448 Q. Nothing in this title shall prohibit the administration of normally self-administered drugs by
1449 unlicensed individuals to a person in his private residence.

1450 R. This section shall not interfere with any prescriber issuing prescriptions in compliance with his
1451 authority and scope of practice and the provisions of this section to a Board agent for use pursuant to
1452 subsection G of § 18.2-258.1. Such prescriptions issued by such prescriber shall be deemed to be valid
1453 prescriptions.

1454 S. Nothing in this title shall prevent or interfere with dialysis care technicians or dialysis patient care
1455 technicians who are certified by an organization approved by the Board of Health Professions or persons
1456 authorized for provisional practice pursuant to Chapter 27.01 (§ 54.1-2729.1 et seq.), in the ordinary
1457 course of their duties in a Medicare-certified renal dialysis facility, from administering heparin, topical
1458 needle site anesthetics, dialysis solutions, sterile normal saline solution, and blood volumizers, for the
1459 purpose of facilitating renal dialysis treatment, when such administration of medications occurs under the
1460 orders of a licensed physician, nurse practitioner, or physician assistant and under the immediate and
1461 direct supervision of a licensed registered nurse. Nothing in this chapter shall be construed to prohibit a
1462 patient care dialysis technician trainee from performing dialysis care as part of and within the scope of
1463 the clinical skills instruction segment of a supervised dialysis technician training program, provided such
1464 trainee is identified as a "trainee" while working in a renal dialysis facility.

1465 The dialysis care technician or dialysis patient care technician administering the medications shall
1466 have demonstrated competency as evidenced by holding current valid certification from an organization
1467 approved by the Board of Health Professions pursuant to Chapter 27.01 (§ 54.1-2729.1 et seq.).

1468 T. Persons who are otherwise authorized to administer controlled substances in hospitals shall be
1469 authorized to administer influenza or pneumococcal vaccines pursuant to § 32.1-126.4.

1470 U. Pursuant to a specific order for a patient and under his direct and immediate supervision, a
1471 prescriber may authorize the administration of controlled substances by personnel who have been
1472 properly trained to assist a doctor of medicine or osteopathic medicine, provided the method does not
1473 include intravenous, intrathecal, or epidural administration and the prescriber remains responsible for

such administration.

V. A physician assistant, nurse or a dental hygienist may possess and administer topical fluoride varnish to the teeth of children aged six months to three years pursuant to an oral or written order or a standing protocol issued by a doctor of medicine, osteopathic medicine, or dentistry that conforms to standards adopted by the Department of Health.

W. A prescriber, acting in accordance with guidelines developed pursuant to § 32.1-46.02, may authorize the administration of influenza vaccine to minors by a licensed pharmacist, registered nurse, licensed practical nurse under the direction and immediate supervision of a registered nurse, or emergency medical services provider who holds an advanced life support certificate issued by the Commissioner of Health when the prescriber is not physically present.

X. Notwithstanding the provisions of § 54.1-3303, pursuant to an oral, written, or standing order issued by a prescriber or a standing order issued by the Commissioner of Health or his designee authorizing the dispensing of naloxone or other opioid antagonist used for overdose reversal in the absence of an oral or written order for a specific patient issued by a prescriber, and in accordance with protocols developed by the Board of Pharmacy in consultation with the Board of Medicine and the Department of Health, a pharmacist may dispense naloxone or other opioid antagonist used for overdose reversal and a person may possess and administer naloxone or other opioid antagonist used for overdose reversal to a person who is believed to be experiencing or about to experience a life-threatening opioid overdose. Law-enforcement officers as defined in § 9.1-101, employees of the Department of Forensic Science, employees of the Office of the Chief Medical Examiner, employees of the Department of General Services Division of Consolidated Laboratory Services, and firefighters who have completed a training program may also possess and administer naloxone in accordance with protocols developed by the Board of Pharmacy in consultation with the Board of Medicine and the Department of Health.

Y. Notwithstanding any other law or regulation to the contrary, a person who is authorized by the Department of Behavioral Health and Developmental Services to train individuals on the administration of naloxone for use in opioid overdose reversal and who is acting on behalf of an organization that provides services to individuals at risk of experiencing an opioid overdose or training in the administration of naloxone for overdose reversal and that has obtained a controlled substances registration from the Board of Pharmacy pursuant to § 54.1-3423 may dispense naloxone to a person who has completed a training program on the administration of naloxone for opioid overdose reversal approved by the Department of Behavioral Health and Developmental Services, provided that such dispensing is (i) pursuant to a standing order issued by a prescriber, (ii) in accordance with protocols developed by the Board of Pharmacy in consultation with the Board of Medicine and the Department of Health, and (iii) without charge or compensation. The dispensing may occur at a site other than that of the controlled substance registration provided the entity possessing the controlled substances registration maintains records in accordance with regulations of the Board of Pharmacy. A person to whom naloxone has been dispensed pursuant to this subsection may possess naloxone and may administer naloxone to a person who is believed to be experiencing or about to experience a life-threatening opioid overdose.

Z. Pursuant to a written order or standing protocol issued by the prescriber within the course of his professional practice, such prescriber may authorize, with the consent of the parents as defined in § 22.1-1, an employee of (i) a school board, (ii) a school for students with disabilities as defined in § 22.1-319 licensed by the Board of Education, or (iii) a private school accredited pursuant to § 22.1-19 as administered by the Virginia Council for Private Education who is trained in the administration of injected medications for the treatment of adrenal crisis resulting from a condition causing adrenal insufficiency to administer such medication to a student diagnosed with a condition causing adrenal insufficiency when the student is believed to be experiencing or about to experience an adrenal crisis. Such authorization shall be effective only when a licensed nurse, nurse practitioner, physician, or physician assistant is not present to perform the administration of the medication.

§ 54.1-3482.1. Certain certification required.

A. The Board shall promulgate regulations establishing criteria for certification of physical therapists to provide certain physical therapy services pursuant to subsection B of § 54.1-3482 without referral from a licensed doctor of medicine, osteopathy, chiropractic, podiatry, or dental surgery, a licensed nurse practitioner practicing in accordance with his practice agreement, *a licensed doctorate of medical science practicing in accordance with his practice agreement*, or a licensed physician assistant acting under the supervision of a licensed physician. The regulations shall include but not be limited to provisions for (i) the promotion of patient safety; (ii) an application process for a one-time certification to perform such procedures; and (iii) minimum education, training, and experience requirements for certification to perform such procedures.

B. The minimum education, training, and experience requirements for certification shall include evidence that the applicant has successfully completed (i) a transitional program in physical therapy as recognized by the Board or (ii) at least three years of active practice with evidence of continuing

1535 education relating to carrying out direct access duties under § 54.1-3482.

1536 **§ 54.1-3812. Release of records.**

1537 A. A veterinarian licensed by the Board shall release or authorize the release of rabies immunization
1538 records and other relevant treatment data of an animal under his care to (i) a requesting physician,
1539 physician assistant, *doctorate of medical science*, or nurse practitioner who is contemplating the
1540 administration of the rabies treatment protocol to any person under his care who has been the victim of
1541 a bite or other possible rabies exposure from such animal; (ii) a requesting animal control officer or
1542 law-enforcement officer who needs to identify the owner of such animal or verify the rabies vaccination
1543 history of such animal; or (iii) a requesting animal control officer or an official of the Department of
1544 Health who is investigating the incident.

1545 B. Any veterinarian licensed by the Board who in good faith releases or authorizes the release of an
1546 animal's rabies immunization records and other relevant data pursuant to this section shall not be liable
1547 for civil damages resulting from the release of such information.